<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12474375</article-id><article-id pub-id-type="pmcid-ver">PMC12474375.1</article-id><article-id pub-id-type="pmcaid">12474375</article-id><article-id pub-id-type="pmcaiid">12474375</article-id><article-id pub-id-type="pmid">41012674</article-id><article-id pub-id-type="doi">10.3390/v17091246</article-id><article-id pub-id-type="publisher-id">viruses-17-01246</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Clinical, Psychosocial, and Structural Factors Associated with the Detection of HIV Drug Resistance in Children Living with HIV in Kisumu, Kenya: Secondary Analysis of Data from the Opt4Kids Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Scallon</surname><given-names initials="AJ">Andrea J.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af1-viruses-17-01246" ref-type="aff">1</xref><xref rid="c1-viruses-17-01246" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-8462-9323</contrib-id><name name-style="western"><surname>Maheria</surname><given-names initials="P">Pooja</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-viruses-17-01246" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oyaro</surname><given-names initials="P">Patrick</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-viruses-17-01246" ref-type="aff">3</xref><xref rid="af4-viruses-17-01246" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Thomas</surname><given-names initials="KK">Katherine K.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af5-viruses-17-01246" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2125-6799</contrib-id><name name-style="western"><surname>Chohan</surname><given-names initials="BH">Bhavna H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af5-viruses-17-01246" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Odhiambo</surname><given-names initials="F">Francesca</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af6-viruses-17-01246" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Brown</surname><given-names initials="E">Evelyn</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af7-viruses-17-01246" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0180-3369</contrib-id><name name-style="western"><surname>Ochomo</surname><given-names initials="E">Edwin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af6-viruses-17-01246" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Karauki</surname><given-names initials="E">Enericah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af7-viruses-17-01246" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Yongo</surname><given-names initials="N">Nashon</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af7-viruses-17-01246" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hassan</surname><given-names initials="SA">Shukri A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af8-viruses-17-01246" ref-type="aff">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bishop</surname><given-names initials="MD">Marley D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af9-viruses-17-01246" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Beck</surname><given-names initials="IA">Ingrid A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af9-viruses-17-01246" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Boyce</surname><given-names initials="C">Ceejay</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af9-viruses-17-01246" ref-type="aff">9</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9566-8959</contrib-id><name name-style="western"><surname>Frenkel</surname><given-names initials="LM">Lisa M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af5-viruses-17-01246" ref-type="aff">5</xref><xref rid="af8-viruses-17-01246" ref-type="aff">8</xref><xref rid="af9-viruses-17-01246" ref-type="aff">9</xref><xref rid="af10-viruses-17-01246" ref-type="aff">10</xref><xref rid="af11-viruses-17-01246" ref-type="aff">11</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1492-5090</contrib-id><name name-style="western"><surname>Abuogi</surname><given-names initials="L">Lisa</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><xref rid="af12-viruses-17-01246" ref-type="aff">12</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-9893-5856</contrib-id><name name-style="western"><surname>Patel</surname><given-names initials="RC">Rena C.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af2-viruses-17-01246" ref-type="aff">2</xref><xref rid="af5-viruses-17-01246" ref-type="aff">5</xref><xref rid="af8-viruses-17-01246" ref-type="aff">8</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Vicenti</surname><given-names initials="I">Ilaria</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Saladini</surname><given-names initials="F">Francesco</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-17-01246"><label>1</label>Elson S. Floyd College of Medicine, Washington State University, Spokane, WA 99202, USA</aff><aff id="af2-viruses-17-01246"><label>2</label>Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA</aff><aff id="af3-viruses-17-01246"><label>3</label>Health Innovations Kenya (HIK), Kisumu 40100, Kenya</aff><aff id="af4-viruses-17-01246"><label>4</label>LVCT Health, Nairobi 00202, Kenya</aff><aff id="af5-viruses-17-01246"><label>5</label>Department of Global Health, University of Washington, Seattle, WA 98105, USA</aff><aff id="af6-viruses-17-01246"><label>6</label>Centre for Microbiology Research, Research Care and Training Program, Kenya Medical Research Institute, Nairobi 00200, Kenya</aff><aff id="af7-viruses-17-01246"><label>7</label>UW Kenya, Nairobi 00200, Kenya</aff><aff id="af8-viruses-17-01246"><label>8</label>Department of Medicine, University of Washington, Seattle, WA 98105, USA</aff><aff id="af9-viruses-17-01246"><label>9</label>Center for Global Infectious Disease Research, Seattle Children&#8217;s Research Institute, Seattle, WA 98101, USA</aff><aff id="af10-viruses-17-01246"><label>10</label>Department of Pediatrics, University of Washington, Seattle, WA 98105, USA</aff><aff id="af11-viruses-17-01246"><label>11</label>Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA</aff><aff id="af12-viruses-17-01246"><label>12</label>Department of Pediatrics, University of Colorado, Denver, CO 80045, USA</aff><author-notes><corresp id="c1-viruses-17-01246"><label>*</label>Correspondence: <email>andrea.scallon@wsu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>9</month><year>2025</year></pub-date><volume>17</volume><issue>9</issue><issue-id pub-id-type="pmc-issue-id">497677</issue-id><elocation-id>1246</elocation-id><history><date date-type="received"><day>25</day><month>7</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>8</month><year>2025</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>28</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-28 18:25:14.327"><day>28</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-17-01246.pdf"/><abstract><p>Background: HIV drug resistance (DR) mutations can compromise antiretroviral therapy (ART) success among children living with HIV (CLHIV). We conducted a secondary analysis using data from a randomized control trial for ART monitoring among CLHIV in Kisumu County, Kenya from 2019 to 2023, to assess clinical, psychosocial, and structural factors associated with HIV DR. Methods: 704 CLHIV were followed for 12+ months, with characteristics captured at enrollment and follow-up visits in the &#8220;parent&#8221; randomized-controlled-trial (of point-of-care plasma viral load testing and for viremias &#8805; 1000 copies/mL HIV genotyping for DR vs. standard-of-care) and an observational &#8220;extension&#8221; substudy (of participants on a dolutegravir-containing ART with genotyping performed on viremic specimens &#8805; 200 copies/mL). A multivariate modified Poisson regression model was used to analyze factors associated with sequences yielding a Stanford HIVDR database DR penalty score (DR-PS) &#8805; 30 to a nucleos(t)ides and/or non-nucleoside reverse transcriptase inhibitor, protease inhibitor (PI), and/or integrase inhibitor (INSTI). Results: Among 113 (16.1%) participants who underwent genotyping, 93 (82.3%) had a DR-PS &#8805; 30. DR-PS &#8805; 30 were associated with age 1&#8211;5 years (adjusted risk ratio (ARR) = 1.84; 95% confidence interval (CI): 1.07, 3.14), history of viremia &#8805; 1000 copies/mL (ARR = 4.18; 95% CI: 2.77, 6.31), prescription of a PI- (ARR = 6.05; 95% CI: 3.43, 10.68) or INSTI-containing regimen (ARR = 1.83; 95% CI: 1.08, 3.11), poor adherence to ART (ARR = 1.91; 95% CI: 1.32, 2.76), lack of caregiver confidence in ART administration (ARR = 1.89; 95% CI: 1.11, 3.22), and mid-sized clinic populations (ARR = 0.55; 95% CI: 0.33, 0.92). Conclusion: Addressing social factors associated with DR-PS &#8805; 30 may improve ART success among CLHIV.</p></abstract><kwd-group><kwd>HIV</kwd><kwd>drug resistance mutation (DRM)</kwd><kwd>children</kwd><kwd>viral failure</kwd><kwd>Kenya</kwd></kwd-group><funding-group><award-group><funding-source>U.S. National Institutes of Health</funding-source><award-id>R34MH115769</award-id><award-id>R01 AI147309</award-id></award-group><award-group><funding-source>Benke Family Gift</funding-source></award-group><award-group><funding-source>IMPAACT</funding-source><award-id>UM1AI068632</award-id><award-id>UM1AI068616</award-id><award-id>UM1AI106716</award-id><award-id>HHSN275201800001I</award-id></award-group><award-group><funding-source>Thrasher Research Fund</funding-source><award-id>TRF15240</award-id></award-group><award-group><funding-source>Emerging Researchers/Clinicians Mentorship Program of the Infectious Disease Society of America</funding-source></award-group><award-group><funding-source>National Center for Advancing Translational Sciences of the NIH</funding-source><award-id>UL1 TR002319</award-id></award-group><funding-statement>This research was funded by the U.S. National Institutes of Health (NIH, R34MH115769, MPI R.C.P., L.A., P.O. and R01 AI147309, MPI L.M.F., G.S.G., P.D.), Benke Family Gift (L.M.F.), IMPAACT (UM1AI068632 [IMPAACT Leadership and Operations Center], UM1AI068616 [IMPAACT Statistical and Data Management Center], UM1AI106716 [IMPAACT Laboratory Center] and HHSN275201800001I; L.M.F) the Thrasher Research Fund (TRF15240), and the Grants for Emerging Researchers/Clinicians Mentorship Program of the Infectious Disease Society of America (A.J.S). Study data were collected and managed using REDCap electronic data capture tools hosted at the University of Washington Institute of Translational Health Sciences and supported by the National Center for Advancing Translational Sciences of the NIH (UL1 TR002319). The funding sources or study sponsors had no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-17-01246"><title>1. Introduction</title><p>Pediatric HIV remains a serious global public health issue, with 2.4 million children living with HIV (CLHIV) &lt; 19 years of age worldwide in 2024 [<xref rid="B1-viruses-17-01246" ref-type="bibr">1</xref>]. Only 59% of CLHIV globally have HIV replication suppressed by antiretroviral therapy (ART), underscoring crucial and life-threatening gaps in optimal care for CLHIV [<xref rid="B1-viruses-17-01246" ref-type="bibr">1</xref>,<xref rid="B2-viruses-17-01246" ref-type="bibr">2</xref>]. African regions remain disproportionately impacted by HIV, accounting for &gt;80% of the HIV burden among CLHIV [<xref rid="B1-viruses-17-01246" ref-type="bibr">1</xref>]. Within the East African region, Kenya has approximately 62,000 CLHIV &lt; 14 years of age and 4300 new infections among children annually [<xref rid="B3-viruses-17-01246" ref-type="bibr">3</xref>]. Despite major advancements in viral load (VL) monitoring, healthcare delivery, and ART regimen availability including use of dolutegravir, ART coverage of CLHIV &lt; 14 years of age in Kenya remains lower, at 70%, than their adult counterparts, with many children not achieving viral suppression (VS) [<xref rid="B3-viruses-17-01246" ref-type="bibr">3</xref>,<xref rid="B4-viruses-17-01246" ref-type="bibr">4</xref>,<xref rid="B5-viruses-17-01246" ref-type="bibr">5</xref>]. Several high-HIV burden African countries, including Kenya, have signed the Dar es Salaam Declaration to commit to eliminating AIDS in children by 2030, yet critical challenges to optimizing VS and eliminating pediatric HIV transmission remain, including HIV drug resistance (DR) [<xref rid="B6-viruses-17-01246" ref-type="bibr">6</xref>].</p><p>The emergence of HIV DR is a substantial threat to the elimination of HIV and the durability of ART, especially for CLHIV who are currently expected to receive life-long therapy. Numerous studies across several African regions have reported alarmingly high prevalence of DR among infants and children, including nearly 85% among CLHIV experiencing low-level viremia in Cameroon, 76% among non-virologically suppressed CLHIV &lt; 19 years old living in Kenya, and up to 50% of infants &lt; 18 months living with HIV in Nigeria [<xref rid="B7-viruses-17-01246" ref-type="bibr">7</xref>,<xref rid="B8-viruses-17-01246" ref-type="bibr">8</xref>,<xref rid="B9-viruses-17-01246" ref-type="bibr">9</xref>]. In our parent study, conducted in Kenya, called &#8220;Optimizing VL suppression in Kenyan children on ART (Opt4Kids)&#8221;, 100% of children experiencing virologic failure (VF), defined as at least one HIV VL &#8805; 1000 copies/mL, had at least one DR mutation (DRM) and 85% had at least one major DRM [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>]. More recently, dolutegravir, an integrase strand transfer inhibitor (INSTI), has emerged as a well-tolerated, safe, and effective treatment for CLHIV, exhibiting easier dosing and a relatively high barrier to DR compared to other ART regimens for CLHIV [<xref rid="B11-viruses-17-01246" ref-type="bibr">11</xref>,<xref rid="B12-viruses-17-01246" ref-type="bibr">12</xref>,<xref rid="B13-viruses-17-01246" ref-type="bibr">13</xref>,<xref rid="B14-viruses-17-01246" ref-type="bibr">14</xref>]. With dolutegravir use rising globally, there are also increasing reports of DR among children on dolutegravir-containing ART [<xref rid="B15-viruses-17-01246" ref-type="bibr">15</xref>,<xref rid="B16-viruses-17-01246" ref-type="bibr">16</xref>,<xref rid="B17-viruses-17-01246" ref-type="bibr">17</xref>,<xref rid="B18-viruses-17-01246" ref-type="bibr">18</xref>]. Especially concerning in low and middle income countries (LMICs), such as Kenya, where availability of ART options are limited and obstacles to diagnostic testing and treatment are abundant, if DR to HIV is not urgently addressed, we risk a rise in HIV strains that are not responsive to any currently available ART and subsequent increases in HIV-related morbidity and mortality [<xref rid="B19-viruses-17-01246" ref-type="bibr">19</xref>,<xref rid="B20-viruses-17-01246" ref-type="bibr">20</xref>].</p><p>The factors driving DR among children in LMICs are numerous, diverse, and closely related to VS, and intertwining individual, social, and systemic influences lay the groundwork for DR acquisition among CLHIV. These factors include, but are not limited to, availability of child-appropriate ART formulations, fluctuations in body weight among children requiring dosing changes, lack of HIV diagnosis disclosure among children, low ART-adherence, perceived low-risk by clinic managers of patients acquiring DR, financial strains, and HIV-related stigma [<xref rid="B8-viruses-17-01246" ref-type="bibr">8</xref>,<xref rid="B21-viruses-17-01246" ref-type="bibr">21</xref>,<xref rid="B22-viruses-17-01246" ref-type="bibr">22</xref>,<xref rid="B23-viruses-17-01246" ref-type="bibr">23</xref>]. To enable effective ART and minimize the emergence of DR, an understanding of the individual-, household-, and societal-level factors that increase one&#8217;s risk for acquiring DR is needed. These insights may help identify subpopulations at greater risk for DR acquisition, determine which patients may be prioritized for treatment changes, and explore which interventions may be most effective to prevent DR. To better define factors associated with DR, we expand on our previous analysis of the Opt4Kids study [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>] by assessing additional predictor variables and by including data from an &#8220;extension&#8221; substudy, or subset of the parent study, of children viremic during dolutegravir-containing ART.</p></sec><sec id="sec2-viruses-17-01246"><title>2. Materials and Methods</title><sec id="sec2dot1-viruses-17-01246"><title>2.1. Study Design and Setting</title><p>This secondary analysis used data from the &#8220;parent&#8221; Opt4Kids study [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>], an open-label randomized control trial examining the impact of point-of-care (POC) VL and targeted DRM testing and clinical decision support among CLHIV on ART, as well as an &#8220;extension&#8221; substudy among a subset of the parent study participants. The parent study protocol and primary results from the Opt4Kids study have been detailed elsewhere [<xref rid="B24-viruses-17-01246" ref-type="bibr">24</xref>,<xref rid="B25-viruses-17-01246" ref-type="bibr">25</xref>]. Largely individual associations, including but not limited to child&#8217;s age, sex, ART regimen, and history of VF, with DRM among children enrolled in the parent Opt4Kids have been previously reported [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>]. Here, we expand our variables to include 17 additional individual-, caregiver-, and household-level clinical, psychosocial, and structural factors. Additionally, we include HIV genotyping for DR from the parent and extension study, and genetic sequences are deposited in GenBank (accession numbers <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide-range" xlink:href="PX310287:PX310455">PX310287-PX310455</ext-link> and NCBI BioProject accession number PRJNA1256474).</p><p>Briefly, the parent Opt4Kids study was conducted from 2019 to 2021 across five low-resource, high-HIV burden, high-volume public sector facilities in Kisumu County, Kenya, a region facing one of the highest burdens of HIV in the country [<xref rid="B26-viruses-17-01246" ref-type="bibr">26</xref>,<xref rid="B27-viruses-17-01246" ref-type="bibr">27</xref>]. Participants were randomized 1:1, stratified by facility and age group (ages 1&#8211;9 and 10&#8211;14 years), to either the intervention or standard-of-care (SOC) arm, and followed for at least 12 months. The intervention group received POC VL testing every 3 months using GeneXpert<sup>&#174;</sup> technology, targeted DRM testing for VL &#8805; 1000 copies/mL, and clinical decision support for providers (i.e., multidisciplinary case review for interpretation of patient DRM testing results) via a clinical management committee. For children in the SOC arm, providers followed national Kenyan Ministry of Health SOC protocols for management of VF among CLHIV, including SOC VL testing every 6 months, enhanced adherence counseling for CLHIV with VF, and limited DRM testing for cases reviewed and approved by the NyaWest HIV Technical Working Group. Specifically, SOC DRM testing was approved for patients who were experiencing VF on first-line protease inhibitor (PI)-containing, or on second- or third-line ART with continued VF. Participants in both intervention and SOC arms underwent POC VL and DRM testing 12 months post-enrollment.</p><p>From 2022 to 2023, we conducted the extension substudy to better understand DR to dolutegravir as part of a larger study [<xref rid="B28-viruses-17-01246" ref-type="bibr">28</xref>]. CLHIV enrolled in the parent study were recruited from four of the five Opt4Kids facilities (the fifth one was excluded due to lowest enrollment numbers and furthest distance from the study team&#8217;s central location). Eligibility included being 1&#8211;14 years old, newly initiating or already receiving ART at one of the study facilities, having a VL &#8805; 200 copies/mL within the last 6 months while on dolutegravir-containing ART, and having caregiver consent. Enrollees were followed every 6 months for a total of an additional 12 months. All samples collected in the extension substudy underwent POC VL testing on site and storage for genotyping at the end of the study. Together, we refer to the parent and extension studies as &#8220;Opt4Kids studies&#8221;.</p><p>Initially in 2019, first-line ART regimens for CLHIV &lt; 14 years of age in Kenya included combinations of two nucleoside reverse transcriptase inhibitors (NRTIs), lamivudine with abacavir or zidovudine, with a non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (preferred for those &gt;3 years of age) or the PI lopinavir/ritonavir (preferred for those &lt;3 years of age). Starting in 2020, dolutegravir was added as the preferred ART regimen for those weighing &gt;35 kg [<xref rid="B29-viruses-17-01246" ref-type="bibr">29</xref>], and in 2022, it became first-line treatment for those weighing &#8805;20 kg [<xref rid="B30-viruses-17-01246" ref-type="bibr">30</xref>,<xref rid="B31-viruses-17-01246" ref-type="bibr">31</xref>]. Optimal second- and third-line ART regimens for CLHIV vary and are determined by genotyping. Second-line ART regimens may include dolutegravir and lamivudine with abacavir or zidovudine, and possible third-line regimens include combinations of darunavir/ritonavir, lamivudine, dolutegravir or etravirine, and abacavir or zidovudine [<xref rid="B31-viruses-17-01246" ref-type="bibr">31</xref>].</p><p>Opt4Kids was ethically and scientifically approved by institutional review boards at AMREF (Kenya) and the University of Washington and University of Colorado (United States), Kenya National Commission for Science, Technology, and Innovation, and the Kenya Pharmacy and Positions Board.</p></sec><sec sec-type="subjects" id="sec2dot2-viruses-17-01246"><title>2.2. Participants and Sample Size</title><p>For this secondary analysis, we included data from all 704 children participating in both the parent and extension Opt4Kids studies. Details on participant exclusion criteria for the parent study are detailed elsewhere [<xref rid="B25-viruses-17-01246" ref-type="bibr">25</xref>]. No power or sample size calculations were conducted for this secondary analysis.</p></sec><sec id="sec2dot3-viruses-17-01246"><title>2.3. Variables</title><sec id="sec2dot3dot1-viruses-17-01246"><title>2.3.1. Primary Analytic Outcome</title><p>The primary analytic outcome is detection of HIV DR to NRTI, NNRTI, PI, or INSTI drug classes at any point during the Opt4Kids studies with a DR penalty score (DR-PS) &#8805; 30 to any antiretroviral (ARV) agent as assessed by the Stanford HIV DR database (HIVdb) [<xref rid="B32-viruses-17-01246" ref-type="bibr">32</xref>] version 9.8 (2025-01-05) accessed on 21 April 2025. For children with &#8805; 2 DR genotypes, the specimen with the greatest DR-PS was analyzed. Sanger sequences in the parent study were generated from viremic specimens with Applied Biosystems HIV-1 Genotyping kit using an Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories [<xref rid="B33-viruses-17-01246" ref-type="bibr">33</xref>,<xref rid="B34-viruses-17-01246" ref-type="bibr">34</xref>] analyzed for DR to NRTI, NNRTI and PI. Sequences from the extension study were derived from viremic specimens while on dolutegravir-containing ART by laboratory-developed methods using PacBio platform or Sanger sequencing (passing NIH Virology Quality Assurance Program) [<xref rid="B28-viruses-17-01246" ref-type="bibr">28</xref>] in Seattle and analyzed for DR to NRTI, NNRTI, PI and INSTI. All sequence analysis used the Stanford HIVdb [<xref rid="B32-viruses-17-01246" ref-type="bibr">32</xref>] version 9.8 (2025-01-05) accessed on 21 April 2025 which assesses together all DRMs affecting each ARV to generate the DR-PS. Despite a DRM penalty score of &#8805;15 predicting low-level DR [<xref rid="B35-viruses-17-01246" ref-type="bibr">35</xref>], there is some consensus that a score of &#8805; 30 is a more clinically significant cutoff to measure DR [<xref rid="B36-viruses-17-01246" ref-type="bibr">36</xref>]. The International Antiviral Society-USA has defined &#8220;major&#8221; and &#8220;minor&#8221; mutations for all drug classes based on expert consensus [<xref rid="B37-viruses-17-01246" ref-type="bibr">37</xref>] which change over time, and because these change over time, we used the DR-PS cutoff approach to make our results more easily reproduceable. In our analysis, participants with DR-PS &lt; 30 are grouped together with participants who did not undergo any DR testing.</p><p>Sensitivity analyses that use DR-PS of &#8805;15 or &#8805;60 are included in the <xref rid="app1-viruses-17-01246" ref-type="app">Supplementary Materials (Table S1)</xref>.</p></sec><sec id="sec2dot3dot2-viruses-17-01246"><title>2.3.2. Associated Risk Factors</title><p>We used each child&#8217;s clinical, caregiver&#8217;s clinical, child&#8217;s psychosocial, caregiver&#8217;s psychosocial, household psychosocial, and structural characteristics collected in the Opt4Kids studies, as detailed below. Some variables were captured only at enrollment (e.g., history of VF prior to study enrollment) while others were captured repeatedly, longitudinally until the end of study follow-up. For repeating measures captured longitudinally (e.g., caregiver intimate partner violence (IPV), stigma, depression), we interpreted and analyzed participants who had experienced a repeating measure at any point (i.e., answered &#8220;yes&#8221;), despite potentially changing responses during follow up, as having experienced the measure.</p></sec><sec id="sec2dot3dot3-viruses-17-01246"><title>2.3.3. Child and Caregiver Clinical Characteristics</title><p>We define clinical characteristics as the personal and clinical attributes that influence an individual&#8217;s health outcome. We include the following child clinical characteristics: age, sex, history of VF within two years prior to study, base drug in ART regimen at time of DR test analysis, and co-administered NRTIs at time of DR test analysis. Of note, for those participants who did not undergo DR testing, we developed a &#8220;proxy&#8221; time of DR test based on the median time from enrollment to DR test used in this analysis for those who did undergo DR testing. We measure the history of VF as any VL result &#8805; 1000 copies/mL within two years prior to parent study enrollment. Clinical characteristics of the caregiver include age and self-reported VS status.</p></sec><sec id="sec2dot3dot4-viruses-17-01246"><title>2.3.4. Child Psychosocial Characteristics</title><p>We define psychosocial characteristics as the traits that arise from the impact of social factors, including interpersonal relationships, community norms, and cultural influences, on behavior and mental health [<xref rid="B38-viruses-17-01246" ref-type="bibr">38</xref>]. The psychosocial child characteristics in our study include school level and type, ART adherence, and awareness of diagnosis. ART adherence is measured as self-report (or caregiver report) as per the national Kenyan guidelines, with adherence to &#8805;95% of medications, 85&#8211;94% of medications, and &lt;85% of medications in the last 30 days being classified as &#8220;good&#8221;, &#8220;inadequate&#8221; and &#8220;poor&#8221;, respectively [<xref rid="B31-viruses-17-01246" ref-type="bibr">31</xref>].</p></sec><sec id="sec2dot3dot5-viruses-17-01246"><title>2.3.5. Caregiver Psychosocial Characteristics</title><p>Caregiver psychosocial characteristics include caregiver marital status, educational attainment, stigma, depression, HIV literacy, medicine administration confidence, and experience of IPV. Caregiver stigma is measured via a modified version of the People Living with HIV (PLHIV) Stigma Index 2.0 survey in Kenya and converted into a binary variable (i.e., yes/no) based on responses of &#8220;agree&#8221; or &#8220;strongly agree&#8221; to survey questions regarding internalized, enacted, and anticipated stigma [<xref rid="B39-viruses-17-01246" ref-type="bibr">39</xref>]. Caregiver depression is measured via the Patient Health Questionnaire 9, with a score of &#8805; 10 indicating having depression [<xref rid="B40-viruses-17-01246" ref-type="bibr">40</xref>]. We evaluate caregivers&#8217; confidence in administering medications by using a de novo 4-point Likert scale developed by our team with responses that range from &#8220;not confident&#8221; to &#8220;very confident&#8221;. In our study, responses of &#8220;very confident&#8221; and &#8220;mostly confident&#8221; are categorized as &#8220;confident&#8221;, while responses of &#8220;somewhat confident&#8221; and &#8220;not confident&#8221; are categorized as &#8220;not confident&#8221;. Caregiver IPV, defined as physical or sexual violence, stalking, or other controlling or aggressive behaviors by an intimate partner [<xref rid="B41-viruses-17-01246" ref-type="bibr">41</xref>], is measured via a modified version of the World Health Organization&#8217;s (WHO) Violence Against Women study instrument [<xref rid="B42-viruses-17-01246" ref-type="bibr">42</xref>] and converted into a binary variable (i.e., yes/no) to represent any IPV experience throughout the study period.</p></sec><sec id="sec2dot3dot6-viruses-17-01246"><title>2.3.6. Household Psychosocial Characteristics</title><p>We define household-level characteristics as attributes of a group of people who regularly share resources, activities, and costs [<xref rid="B43-viruses-17-01246" ref-type="bibr">43</xref>]. For household-level psychosocial characteristics, we include food insecurity, other children living in the home, and other CLHIV living in the home. Food insecurity is measured via the Household Food Insecurity Access Scale which includes categories of food secure, mildly food insecure, moderately food insecure, and severely food insecure [<xref rid="B44-viruses-17-01246" ref-type="bibr">44</xref>]. Participants whose score corresponds to &#8220;mildly food insecure&#8221;, &#8220;moderately food insecure,&#8221; or &#8220;severely food insecure&#8221; are categorized as &#8220;food insecure,&#8221; while participants whose score corresponds to &#8220;food secure&#8221; are categorized as &#8220;food secure&#8221;.</p></sec><sec id="sec2dot3dot7-viruses-17-01246"><title>2.3.7. Structural Characteristics</title><p>We define structural characteristics as institutional, cultural, and policy-related factors that influence patterns of advantage and overall health [<xref rid="B45-viruses-17-01246" ref-type="bibr">45</xref>], including rurality, travel time, and clinic volume. Rurality is defined as clinic location (i.e., urban, semi-urban, or rural) and travel time from their primary residence to the facility was self-reported by caregivers at enrollment. Clinic volume is classified as high, medium, or low based on HIV patient visits per month at the facility.</p></sec></sec><sec id="sec2dot4-viruses-17-01246"><title>2.4. Data Sources and Management</title><p>Trained research staff used direct, electronic data entry to collect data via tablets onto standardized collection forms created in REDCap. Collected data included demographic, clinical (e.g., health indicators), and laboratory data, including VL and DR results, acquired from routine medical records, a national online VL database, and facility laboratory logbooks. Research staff also administered questionnaires, in-person or by phone, for self-reported data. Validated instruments were utilized in the questionnaires where available.</p></sec><sec id="sec2dot5-viruses-17-01246"><title>2.5. Statistical Methods</title><p>We performed descriptive analyses, utilizing frequencies and percentages. We report on the prevalence of HIV DR by specific ARV medication using a DR-PS &#8805; 30 as defined by the Stanford HIVdb. We utilized a modified Poisson regression model with a log link and robust standard error estimations, as we have done in the primary outcomes analysis [<xref rid="B25-viruses-17-01246" ref-type="bibr">25</xref>]. We report unadjusted and adjusted relative risk and 95% confidence intervals, with statistical significance set at <italic toggle="yes">p</italic> &lt; 0.20 for potential predictor variables to be included from the univariate models in the multivariate model. Statistical analyses were conducted using Python version 3.11.5.</p></sec></sec><sec sec-type="results" id="sec3-viruses-17-01246"><title>3. Results</title><sec sec-type="subjects" id="sec3dot1-viruses-17-01246"><title>3.1. Individual, Household, and Structural Characteristics of Participants</title><p>A total of 704 CLHIV were enrolled in the parent study with a median age of 10 years (interquartile range [IQR] 7, 12) (<xref rid="viruses-17-01246-f001" ref-type="fig">Figure 1</xref>; <xref rid="viruses-17-01246-t001" ref-type="table">Table 1</xref>). Of the 704 CLHIV from the parent study, 74 were enrolled in the extension substudy. The participants&#8217; ART regimens at the time of their greatest DR-PS or if no viremias, at time of their first DR test, include 363 (51.6%) on NNRTI-containing regimens, 285 (40.5%) on PI-containing regimens, 55 (7.8%) on INSTI-containing regimens, and 1 (0.1%) was on an NRTI-only regimen. The most common full ART regimens at this time were abacavir/lamivudine/efavirenz, abacavir/lamivudine/lopinarvir/ritonavir, and zidovudine/lamivudine/lopinavir/ritonavir. A history of VF within two years prior to enrolling into the parent study was reported for 144 (20.5%) participants. Primary caregivers were mostly over the age of 24 years (<italic toggle="yes">n</italic> = 661, 93.9%) and, among those living with HIV were virally suppressed (<italic toggle="yes">n</italic> = 431, 61.2%). Some caregivers experienced depression (<italic toggle="yes">n</italic> = 252, 35.8%), held HIV-related stigmatizing beliefs (<italic toggle="yes">n</italic> = 105, 14.9%), or experienced IPV (<italic toggle="yes">n</italic> = 163, 23.2%). Nearly all participant households experienced some food insecurity over the study period (<italic toggle="yes">n</italic> = 687, 97.6%). Participants largely attended clinics in urban (<italic toggle="yes">n</italic> = 421, 59.8%) or semi-urban areas (<italic toggle="yes">n</italic> = 158, 22.4%).</p></sec><sec id="sec3dot2-viruses-17-01246"><title>3.2. HIV Drug Resistance (DR) Testing and DR Penalty Scores (DR-PS) &#8805; 30</title><p>Among the 704 CLHIV, 113 (16.1%) had 190 DR tests throughout the study periods, of which 93 (82.3%) had DR-PS &#8805; 30 in one or more test results (<xref rid="viruses-17-01246-t001" ref-type="table">Table 1</xref>). In comparison to the 591 (83.9%) CLHIV without testing combined with the 20 (2.8%) with a DR-PS &lt; 30, those with DR-PS &#8805; 30 were more likely to have a history of VF within two years prior to the parent study (14.2% vs. 61.3%), have poor adherence (18.3% vs. 36.6%) be on a PI- (39.3% vs. 48.4%) or INSTI-containing (4.4% vs. 30.1%) regimen at time of DR test analysis, and be age 1&#8211;5 years (9.0% vs. 25.8%).</p><p>Across the 93 participants with any DRM assessed by Stanford HIVdb, NRTI and NNRTI associated mutations were most prevalent and included M184I/MIV/MV/V (50%), L74V/I (13%), and Y115F/YF (13%), and K103N/KM/KN (28%), G190A/E/GA (19%), and Y181C/YC (11%), respectively (<xref rid="viruses-17-01246-f002" ref-type="fig">Figure 2</xref>b,c). PI (<italic toggle="yes">n</italic> = 6, 6.5%) or INSTI (<italic toggle="yes">n</italic> = 5, 5.4%) mutations were less common (<xref rid="viruses-17-01246-f002" ref-type="fig">Figure 2</xref>d,e). Importantly, over 70% of the 93 participants had DR conferring resistance to emtricitabine and lamivudine. Over 80% had DR to efavirenz (<italic toggle="yes">n</italic> = 82, 88.2%) and nevirapine (<italic toggle="yes">n</italic> = 82, 88.2%), with fewer conferring cross-resistance to rilpivirine (<italic toggle="yes">n</italic> = 36, 38.7%) (<xref rid="viruses-17-01246-f003" ref-type="fig">Figure 3</xref>). Few (&lt;5%) of these participants&#8217; sequences encoded DR to PI and INSTI. Most participants were resistant to multiple ARVs within a drug class. 82 (88.2%) participants had a DR-PS &#8805; 30 to two or more NNRTIs, and 69 (74.2%) had a DR-PS &#8805; 30 to two or more NRTIs (<xref rid="viruses-17-01246-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot3-viruses-17-01246"><title>3.3. Associations with DR-PS &#8805; 30</title><sec><title>Individual, Household, and Structural Characteristics</title><p>Comparisons of participants&#8217; risk factors between those with versus without DR-PS &#8805; 30 found that DR-PS &#8805; 30 was associated with children&#8217;s age of 1&#8211;5 years, history of VF within two years prior to study enrollment, PI- or INSTI-containing regimens at time of DR test analysis, self-reported poor adherence, and lack of caregiver drug administration confidence (<xref rid="viruses-17-01246-t002" ref-type="table">Table 2</xref>; <xref rid="viruses-17-01246-f004" ref-type="fig">Figure 4</xref>). Receiving HIV care at a clinic with a midsized population was associated with a DR-PS &lt; 30. A DR-PS &#8805; 30 was not significantly associated with sex, ART-base, co-administered NRTIs, food insecurity, school level, school type, child awareness of status, multiple factors related to participants&#8217; caregivers (i.e., marital status, age, VS, educational attainment, depression, stigma, HIV literacy, IPV), having other children or CLHIV in the home, travel time to the clinic, or clinic location.</p></sec></sec></sec><sec sec-type="discussion" id="sec4-viruses-17-01246"><title>4. Discussion</title><p>Given that CLHIV currently need life-long ART, there is an urgent need to address the underlying social causes of ART non-suppression and selection of HIV DR to ensure longevity of already-limited therapy regimens [<xref rid="B46-viruses-17-01246" ref-type="bibr">46</xref>]. Our study confirms risk factors identified in our earlier analysis of Opt4Kids cohort [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>] plus identifies novel risk factors associated with DR. We confirm that HIV DR (defined by a Stanford HIVdb DR-PS &#8805; 30) is associated with a younger age (1&#8211;5 years) [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>], a history of VF [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>], and being prescribed a PI- [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>] or INSTI-containing regimen at time of DR test analysis (the latter two likely being surrogate markers for HIV treatment experience). Newly identified caregiver, psychosocial, and structural factors, including self-reported poor adherence and a lack of caregiver confidence in ART administration were found to be associated with DR, and attending a clinic with a midsized population was found to be protective against having any DR. In this analysis, we also reveal that food insecurity, awareness of status, and caregiver factors (e.g., depression, VS, stigma, educational attainment, IPV, or HIV literacy) are not associated with HIV DR.</p><p>The detection of HIV DR to dolutegravir was low (&lt;5%) across participants tested during viremic episodes. The paucity of DR to dolutegravir is likely due in part to relatively few people observed during dolutegravir-based ART and most achieving sustained suppression of HIV replication. However, several participants had high prevalence of resistance to multiple NRTIs, including lamivudine and tenofovir, which has the potential to render some children on functional dolutegravir monotherapy [<xref rid="B28-viruses-17-01246" ref-type="bibr">28</xref>].</p><p>The significant associations identified in our analysis (e.g., base drug in ART regimen at time of DR test analysis, etc.) could potentially be driven by any specific HIV DRM, including but not limited to K103N or Y181C, although not directly assessed in our analysis. Prior studies have corroborated how individual-, household-, and societal-level clinical, psychosocial, and structural vulnerabilities impact VS and adherence, yet fewer studies have indicated how these factors influence DRM acquisition [<xref rid="B47-viruses-17-01246" ref-type="bibr">47</xref>,<xref rid="B48-viruses-17-01246" ref-type="bibr">48</xref>,<xref rid="B49-viruses-17-01246" ref-type="bibr">49</xref>,<xref rid="B50-viruses-17-01246" ref-type="bibr">50</xref>]. A study conducted among a group of children and adolescents in rural southern Tanzania indicated that younger age, female sex, and poor adherence were risk factors for acquisition of HIV DR, mostly consistent with our findings [<xref rid="B51-viruses-17-01246" ref-type="bibr">51</xref>]. Conceptualizing the development of DR as solely due to biomedical or clinical factors at the individual level may be limiting. Thus, our current analysis, that moves beyond individual-level clinical factors to start examining caregiver- and household-level factors that intersect with psychosocial and structural elements, remains relevant. In our study, the relationship between individual factors with DR acquisition may exist due to wider, underlying social or structural reasons, including but not limited to poverty, stigma, gender inequality, and social norms [<xref rid="B52-viruses-17-01246" ref-type="bibr">52</xref>,<xref rid="B53-viruses-17-01246" ref-type="bibr">53</xref>]. For example, unequal access to economic resources and systemically reinforced norms, including fear of blame or ridicule by peers after HIV status disclosure and expectations of females in regard to sexual behavior, reduce females&#8217; uptake of HIV testing, services, and treatment, potentially explaining why female sex in has shown to be a significant risk factor for DR acquisition among other studies [<xref rid="B51-viruses-17-01246" ref-type="bibr">51</xref>,<xref rid="B52-viruses-17-01246" ref-type="bibr">52</xref>,<xref rid="B53-viruses-17-01246" ref-type="bibr">53</xref>,<xref rid="B54-viruses-17-01246" ref-type="bibr">54</xref>]. When designing interventions to address the rise in DR, Campbell and Cornish&#8217;s conceptualization of social context offers a useful model, drawing on three dimensions that shape social environments, including material (e.g., resources, economic status), symbolic (e.g., meanings, ideologies, and norms), and relational (e.g., leadership and relationships with outside organizations, politicians, etc.) contexts [<xref rid="B55-viruses-17-01246" ref-type="bibr">55</xref>]. Effectively addressing DR acquisition among girls and women, then, goes beyond overcoming individual-level challenges to HIV care and also calls for a shared commitment by local agencies and leadership in all levels of the government to provide tailored structural programs that confront the underlying norms of stigma, violence, and unequal access to economic resources that may contribute to DR acquisition [<xref rid="B55-viruses-17-01246" ref-type="bibr">55</xref>,<xref rid="B56-viruses-17-01246" ref-type="bibr">56</xref>,<xref rid="B57-viruses-17-01246" ref-type="bibr">57</xref>,<xref rid="B58-viruses-17-01246" ref-type="bibr">58</xref>,<xref rid="B59-viruses-17-01246" ref-type="bibr">59</xref>]. Thus, comprehensively addressing the deeper social contexts and environments through which DR emerges and creating &#8220;health-enabling social environments&#8221;, or social environments that promote and support health-enhancing behavior, may help shape future interventions that tackle DR acquisition to better address the social root causes of this issue [<xref rid="B55-viruses-17-01246" ref-type="bibr">55</xref>].</p><p>We anticipated that living farther away from a treatment facility, a potential barrier to maintaining consistent care, would be associated with DR; seemingly paradoxically, our analysis suggests that living farther from a facility, a structural factor, may serve as a protective factor to DR acquisition, although the relationship was not statistically significant. According to existing literature across various African regions, it is not uncommon for PLHIV to travel beyond their nearest facility to receive care, with one study in rural South Africa showing that PLHIV were nearly four times more likely to travel greater distances than patients seeking care for other health issues [<xref rid="B60-viruses-17-01246" ref-type="bibr">60</xref>,<xref rid="B61-viruses-17-01246" ref-type="bibr">61</xref>,<xref rid="B62-viruses-17-01246" ref-type="bibr">62</xref>]. Travelling farther distances from home communities to seek care could provide privacy, or anonymity, indirectly promoting PLHIV to attend appointments and adhere to treatment while avoiding stigma, discrimination, and social exclusion due to inadvertent disclosure [<xref rid="B61-viruses-17-01246" ref-type="bibr">61</xref>,<xref rid="B62-viruses-17-01246" ref-type="bibr">62</xref>,<xref rid="B63-viruses-17-01246" ref-type="bibr">63</xref>]. Yet, our study finds that caregiver stigma was not associated with acquisition of DR, suggesting alternative explanations for travelling farther to seek care may exist. Other studies have suggested that PLHIV may travel greater distances due to a lack of knowledge of nearby facilities, or to seek specialized HIV care at facilities with higher perceived quality of care, such as at tertiary hospitals [<xref rid="B61-viruses-17-01246" ref-type="bibr">61</xref>,<xref rid="B64-viruses-17-01246" ref-type="bibr">64</xref>]. While some people to travel greater distances to seek care, data from multiple studies find that transportation-related barriers, including distance, high transportation costs, poor road conditions, or lack of reliable transportation, are associated with decreased levels of ART adherence, increased rates of defaulting on ART, and reduced use of voluntary counselling and testing services across several African regions [<xref rid="B65-viruses-17-01246" ref-type="bibr">65</xref>]. Additional research could better define intricacies of factors, such as stigma or improved perceived quality of care, that drive individuals to travel farther to seek HIV care in a manner that allows better treatment of these issues by caregivers.</p><p>While our quantitative analysis has strengths in understanding potential predictors of pediatric HIV DR and current challenges in addressing DR in Kenya, the study also has several limitations. First, our interpretations do not account for the timing or the circumstances through which DR was acquired among participants. For example, among children currently on INSTI-containing regimens, mutations may have been previously selected while receiving NNRTI- or PI-containing ART. We did not assess longitudinal data measuring when mutations were selected, so our analyses should be interpreted with an understanding that mutations may have simply persisted on prior regimens rather than being newly selected on current regimens. Secondly, a significant portion of data was self-reported by caregivers, rather than obtained via objective measures, so social desirability bias, etc., may exist. Third, our study lacks more measures of social or structural vulnerability to various HIV outcomes; a more comprehensive approach to understanding social contexts, including the material, symbolic, and relational contexts can better inform future work. Lastly, our analysis largely considers presence of DR as a proxy for viremia, largely due to non-adherence, and not DR necessitating a regimen change from the current one (our analysis of DR leading to changes in regimen and improvement in VS from the parent study are reported elsewhere [<xref rid="B10-viruses-17-01246" ref-type="bibr">10</xref>]). Lastly, our parent study did not analyze sequence data encoding integrase, and while captured in our extension substudy, which found the prevalence of DR was low, relatively few children were followed for a short time while on dolutegravir-containing ART.</p></sec><sec sec-type="conclusions" id="sec5-viruses-17-01246"><title>5. Conclusions</title><p>Our study emphasizes that multiple individual- and household-level clinical, psychosocial, and structural factors must be addressed to enable ART suppression of HIV replication and avoid selection of DR. In our cohort, assisting families with ART adherence and boosting caregiver confidence in ART administration could increase rates of ART suppression. Next steps could include development of interventions that identify individuals and their families at risk for DR acquisition or enhancing education and counseling at the clinic level. Additional research is needed to elucidate the pathways, especially the social contexts, through which these factors might influence and be modified for treatment success among CLHIV.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank all the Opt4Kids study team members and all study participants.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-viruses-17-01246"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/v17091246/s1">https://www.mdpi.com/article/10.3390/v17091246/s1</uri>, Table S1: Factors associated with any potentially significant drug resistance mutation among children enrolled in Opt4Kids studies, using penalty scores &#8805; 15 and &#8805; 60 (<italic toggle="yes">n</italic> = 704).</p><supplementary-material id="viruses-17-01246-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="viruses-17-01246-s001.zip" position="float" orientation="portrait"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, R.C.P., A.J.S.; methodology, L.A., R.C.P., P.O., K.K.T. and B.H.C.; software: N.Y.; formal analysis, A.J.S., P.M., R.C.P., B.H.C., K.K.T., M.D.B., I.A.B., C.B. and L.M.F.; investigation, L.A., R.C.P., P.O., K.K.T., F.O. and E.K.; resources, P.O., L.A., R.C.P., E.K., K.K.T. and N.Y.; data curation, P.M.; writing&#8212;original draft preparation, A.J.S., R.C.P. and P.M.; writing&#8212;review and editing, all; visualization, P.M. and A.J.S.; supervision, P.O., E.K., N.Y., S.A.H., E.O., E.B., R.C.P. and L.A.; project administration, all; funding acquisition, L.M.F., R.C.P., L.A. and P.O. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Boards at the African Medical and Research Foundation (AMREF) (Protocol P545, approved 27 November 2018) and Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Protocol GEN/21A/V94, approved 19 September 2019) in Kenya, as well as the University of Washington (Protocol 00004861, approved 1 June 2018) and the University of Colorado Denver (Protocol 18-1702, approved 2 October 2018) in the United States.</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all subjects involved in the study.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The de-identified data, data codebook, and other data elements outlined in this study are available upon request from the corresponding author, ethics approval, submission of relevant documents, and signed data access agreement.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-17-01246"><label>1.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>UNICEF</collab></person-group><article-title>Global and Regional Trends</article-title><comment>Updated July 2025</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://data.unicef.org/topic/hivaids/global-regional-trends/" ext-link-type="uri">https://data.unicef.org/topic/hivaids/global-regional-trends/</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-08-18">(accessed on 18 August 2025)</date-in-citation></element-citation></ref><ref id="B2-viruses-17-01246"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>W.M.</given-names></name><name name-style="western"><surname>Law</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Egger</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wools-Kaloustian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moore</surname><given-names>R.</given-names></name><name name-style="western"><surname>McGowan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kumarasamy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Desmonde</surname><given-names>S.</given-names></name><name name-style="western"><surname>Edmonds</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>M.-A.</given-names></name><etal/></person-group><article-title>Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: A multiregional, retrospective cohort study in 31 countries</article-title><source>Lancet HIV</source><year>2021</year><volume>8</volume><fpage>e766</fpage><lpage>e775</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(21)00265-4</pub-id><pub-id pub-id-type="pmid">34856180</pub-id><pub-id pub-id-type="pmcid">PMC8782625</pub-id></element-citation></ref><ref id="B3-viruses-17-01246"><label>3.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>Kenya HIV and AIDS Estimates</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unaids.org/en/regionscountries/countries/kenya" ext-link-type="uri">https://www.unaids.org/en/regionscountries/countries/kenya</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-08-18">(accessed on 18 August 2025)</date-in-citation></element-citation></ref><ref id="B4-viruses-17-01246"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mulinge</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Kibui</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Kimani</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wainaina</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bwana</surname><given-names>P.</given-names></name><name name-style="western"><surname>Omondi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wafula</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wamalwa</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Omondi</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Nduati</surname><given-names>R.W.</given-names></name><etal/></person-group><article-title>Factors associated with viral load non-suppression among treatment-experienced pre-teenage children living with HIV in Kenya: A nationwide population-based cohort study, 2015&#8211;2021</article-title><source>eClinicalMedicine</source><year>2024</year><volume>68</volume><fpage>102454</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102454</pub-id><pub-id pub-id-type="pmid">38333535</pub-id><pub-id pub-id-type="pmcid">PMC10850406</pub-id></element-citation></ref><ref id="B5-viruses-17-01246"><label>5.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>UNAIDS</collab></person-group><article-title>New High-Quality Antiretroviral Therapy to be Launched in South Africa, Kenya and over 90 Low-and Middle-Income Countries at Reduced Price</article-title><comment>Published 21 September 2017</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/September/20170921_TLD#:~:text=&#x201C;Research%20has%20shown20%that%20dolutegravir,in%20the%20National%20ART%20Pro-gram.%E@%80%9D" ext-link-type="uri">https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/September/20170921_TLD#:~:text=&#8220;Research%20has%20shown20%that%20dolutegravir,in%20the%20National%20ART%20Pro-gram.%E@%80%9D</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-20">(accessed on 20 July 2025)</date-in-citation></element-citation></ref><ref id="B6-viruses-17-01246"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Lancet HIV</collab></person-group><article-title>Declaration commits to ending AIDS in children</article-title><source>Lancet HIV</source><year>2023</year><volume>10</volume><fpage>e209</fpage><pub-id pub-id-type="doi">10.1016/S2352-3018(23)00057-7</pub-id><pub-id pub-id-type="pmid">37001960</pub-id></element-citation></ref><ref id="B7-viruses-17-01246"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inzaule</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Osi</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Akinbiyi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Emeka</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khamofu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mpazanje</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ilesanmi</surname><given-names>O.</given-names></name><name name-style="western"><surname>Ndembi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Odafe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sigaloff</surname><given-names>K.C.E.</given-names></name><etal/></person-group><article-title>High Prevalence of HIV Drug Resistance Among Newly Diagnosed Infants Aged &lt;18 Months: Results From a Nationwide Surveillance in Nigeria</article-title><source>JAIDS J. Acquir. Immune Defic. Syndr.</source><year>2018</year><volume>77</volume><fpage>e1</fpage><lpage>e7</lpage><pub-id pub-id-type="pmid">28961680</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000001553</pub-id></element-citation></ref><ref id="B8-viruses-17-01246"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsikhutsu</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bii</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dear</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kasembeli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sing&#8217;oEi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rombosia</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ochieng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wolfman</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Prevalence and Correlates of Viral Load Suppression and Human Immunodeficiency Virus (HIV) Drug Resistance Among Children and Adolescents in South Rift Valley and Kisumu, Kenya</article-title><source>Clin. Infect. Dis.</source><year>2022</year><volume>75</volume><fpage>936</fpage><lpage>944</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac059</pub-id><pub-id pub-id-type="pmid">35092424</pub-id><pub-id pub-id-type="pmcid">PMC9522406</pub-id></element-citation></ref><ref id="B9-viruses-17-01246"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Djiyou</surname><given-names>A.B.D.</given-names></name><name name-style="western"><surname>I Penda</surname><given-names>C.</given-names></name><name name-style="western"><surname>Madec</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ngondi</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Moukoko</surname><given-names>A.</given-names></name><name name-style="western"><surname>E Eboumbou</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aghokeng</surname><given-names>A.F.</given-names></name></person-group><article-title>Prevalence of HIV drug resistance among adolescents receiving ART in Cameroon with low- or high-level viraemia</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>2938</fpage><lpage>2942</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad334</pub-id><pub-id pub-id-type="pmid">37921335</pub-id></element-citation></ref><ref id="B10-viruses-17-01246"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abuogi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Oyaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wakjira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Scallon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Mukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chohan</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.</given-names></name><name name-style="western"><surname>Karauki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yongo</surname><given-names>N.</given-names></name><etal/></person-group><article-title>HIV Drug Resistance Patterns and Characteristics Associated with Clinically Significant Drug Resistance among Children with Virologic Failure on Antiretroviral Treatment in Kenya: Findings from the Opt4Kids Randomized Controlled Trial</article-title><source>Viruses</source><year>2023</year><volume>15</volume><elocation-id>2083</elocation-id><pub-id pub-id-type="doi">10.3390/v15102083</pub-id><pub-id pub-id-type="pmid">37896860</pub-id><pub-id pub-id-type="pmcid">PMC10612029</pub-id></element-citation></ref><ref id="B11-viruses-17-01246"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Makoni</surname><given-names>M.</given-names></name></person-group><article-title>The promise of paediatric dolutegravir in Zimbabwe</article-title><source>Lancet HIV</source><year>2022</year><volume>9</volume><fpage>e603</fpage><lpage>e604</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(22)00223-5</pub-id><pub-id pub-id-type="pmid">36055292</pub-id></element-citation></ref><ref id="B12-viruses-17-01246"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacha</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Dlamini</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Anabwani</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gwimile</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kanywa</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Farirai</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bvumbwe</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tsotako</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steffy</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa</article-title><source>Pediatr. Infect. Dis. J.</source><year>2023</year><volume>42</volume><fpage>576</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1097/INF.0000000000003878</pub-id><pub-id pub-id-type="pmid">36795586</pub-id><pub-id pub-id-type="pmcid">PMC10259212</pub-id></element-citation></ref><ref id="B13-viruses-17-01246"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frange</surname><given-names>P.</given-names></name><name name-style="western"><surname>Avettand-Fenoel</surname><given-names>V.</given-names></name><name name-style="western"><surname>Veber</surname><given-names>F.</given-names></name><name name-style="western"><surname>Blanche</surname><given-names>S.</given-names></name></person-group><article-title>Similar efficacy and safety of dolutegravir between age groups of HIV-1-infected paediatric and young adult patients aged 5 years and older</article-title><source>HIV Med.</source><year>2019</year><volume>20</volume><fpage>561</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.1111/hiv.12752</pub-id><pub-id pub-id-type="pmid">31140725</pub-id></element-citation></ref><ref id="B14-viruses-17-01246"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viani</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Ruel</surname><given-names>T.</given-names></name><name name-style="western"><surname>Alvero</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>T.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Hazra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Townley</surname><given-names>E.</given-names></name><name name-style="western"><surname>Palumbo</surname><given-names>P.</given-names></name><name name-style="western"><surname>Buchanan</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Vavro</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2020</year><volume>9</volume><fpage>159</fpage><lpage>165</lpage><pub-id pub-id-type="doi">10.1093/jpids/piy139</pub-id><pub-id pub-id-type="pmcid">PMC7192395</pub-id><pub-id pub-id-type="pmid">30951600</pub-id></element-citation></ref><ref id="B15-viruses-17-01246"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamori</surname><given-names>D.</given-names></name><name name-style="western"><surname>Barabona</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rugemalila</surname><given-names>J.</given-names></name><name name-style="western"><surname>Maokola</surname><given-names>W.</given-names></name><name name-style="western"><surname>Masoud</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Mizinduko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabasaba</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruhago</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sambu</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mushi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Emerging integrase strand transfer inhibitor drug resistance mutations among children and adults on ART in Tanzania: Findings from a national representative HIV drug resistance survey</article-title><source>J. Antimicrob. Chemother.</source><year>2023</year><volume>78</volume><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1093/jac/dkad010</pub-id><pub-id pub-id-type="pmid">36680436</pub-id></element-citation></ref><ref id="B16-viruses-17-01246"><label>16.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>HIV Drug Resistance: Brief Report 2024</article-title><comment>Published 2024</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/9789240086319" ext-link-type="uri">https://www.who.int/publications/i/item/9789240086319</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-20">(accessed on 20 July 2025)</date-in-citation></element-citation></ref><ref id="B17-viruses-17-01246"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malinga</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Archary</surname><given-names>M.</given-names></name></person-group><article-title>Breaking the unbreakable: A paediatric case of dolutegravir resistance from KwaZulu-Natal</article-title><source>S. Afr. J. HIV Med.</source><year>2023</year><volume>24</volume><fpage>1458</fpage><pub-id pub-id-type="doi">10.4102/sajhivmed.v24i1.1458</pub-id><pub-id pub-id-type="pmcid">PMC10244928</pub-id><pub-id pub-id-type="pmid">37293603</pub-id></element-citation></ref><ref id="B18-viruses-17-01246"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brenner</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Wainberg</surname><given-names>M.A.</given-names></name></person-group><article-title>Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance</article-title><source>Virus Res.</source><year>2017</year><volume>239</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2016.07.006</pub-id><pub-id pub-id-type="pmid">27422477</pub-id></element-citation></ref><ref id="B19-viruses-17-01246"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boerma</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Boender</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>van Hensbroek</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Rinke de Wit</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Sigaloff</surname><given-names>K.C.E.</given-names></name></person-group><article-title>Sequencing paediatric antiretroviral therapy in the context of a public health approach</article-title><source>J. Int. AIDS Soc.</source><year>2015</year><volume>18</volume><issue>(Suppl. S6)</issue><fpage>20265</fpage><pub-id pub-id-type="doi">10.7448/IAS.18.7.20265</pub-id><pub-id pub-id-type="pmid">26639116</pub-id><pub-id pub-id-type="pmcid">PMC4670836</pub-id></element-citation></ref><ref id="B20-viruses-17-01246"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scallon</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Oyaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wagude</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kinywa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oluoch</surname><given-names>F.</given-names></name><etal/></person-group><article-title>&#8220;I feel drug resistance testing allowed us to make an informed decision&#8221;: Qualitative insights on the role of HIV drug resistance mutation testing among children and pregnant women living with HIV in western Kenya</article-title><source>BMC Health Serv. Res.</source><year>2023</year><volume>23</volume><fpage>908</fpage><pub-id pub-id-type="doi">10.1186/s12913-023-09804-x</pub-id><pub-id pub-id-type="pmid">37620855</pub-id><pub-id pub-id-type="pmcid">PMC10463841</pub-id></element-citation></ref><ref id="B21-viruses-17-01246"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiekens</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Casterl&#233;</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Pellizzer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mosha</surname><given-names>I.H.</given-names></name><name name-style="western"><surname>Mosha</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>T.F.R.</given-names></name><name name-style="western"><surname>Sangeda</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Surian</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vandaele</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vranken</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Exploring the mechanisms behind HIV drug resistance in sub-Saharan Africa: Conceptual mapping of a complex adaptive system based on multi-disciplinary expert insights</article-title><source>BMC Public Health</source><year>2022</year><volume>22</volume><fpage>455</fpage><pub-id pub-id-type="doi">10.1186/s12889-022-12738-4</pub-id><pub-id pub-id-type="pmid">35255842</pub-id><pub-id pub-id-type="pmcid">PMC8899794</pub-id></element-citation></ref><ref id="B22-viruses-17-01246"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bertagnolio</surname><given-names>S.</given-names></name><name name-style="western"><surname>De Luca</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vitoria</surname><given-names>M.</given-names></name><name name-style="western"><surname>Essajee</surname><given-names>S.</given-names></name><name name-style="western"><surname>Penazzato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>McClure</surname><given-names>C.</given-names></name><name name-style="western"><surname>Duncombe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M.R.</given-names></name></person-group><article-title>Determinants of HIV Drug Resistance and Public Health Implications in Low- and Middle-Income Countries</article-title><source>Antivir. Ther.</source><year>2012</year><volume>17</volume><fpage>941</fpage><lpage>953</lpage><pub-id pub-id-type="doi">10.3851/IMP2320</pub-id><pub-id pub-id-type="pmid">22898622</pub-id></element-citation></ref><ref id="B23-viruses-17-01246"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernheimer</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Patten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Makeleni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Mantangana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dumile</surname><given-names>N.</given-names></name><name name-style="western"><surname>Goemaere</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>V.</given-names></name></person-group><article-title>Paediatric HIV treatment failure: A silent epidemic</article-title><source>J. Int. AIDS Soc.</source><year>2015</year><volume>18</volume><fpage>20090</fpage><pub-id pub-id-type="doi">10.7448/IAS.18.1.20090</pub-id><pub-id pub-id-type="pmid">26208630</pub-id><pub-id pub-id-type="pmcid">PMC4514899</pub-id></element-citation></ref><ref id="B24-viruses-17-01246"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Oyaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Odeny</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wagude</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kinywa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oluoch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Odhiambo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Optimizing viral load suppression in Kenyan children on antiretroviral therapy (Opt4Kids)</article-title><source>Contemp. Clin. Trials Commun.</source><year>2020</year><volume>20</volume><fpage>100673</fpage><pub-id pub-id-type="doi">10.1016/j.conctc.2020.100673</pub-id><pub-id pub-id-type="pmid">33195874</pub-id><pub-id pub-id-type="pmcid">PMC7644580</pub-id></element-citation></ref><ref id="B25-viruses-17-01246"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Oyaro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Wagude</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>E.</given-names></name><name name-style="western"><surname>A Hassan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kinywa</surname><given-names>E.</given-names></name><name name-style="western"><surname>Oluoch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Odhiambo</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): An open-label, randomised controlled trial</article-title><source>Lancet Child Adolesc. Health</source><year>2022</year><volume>6</volume><fpage>681</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/S2352-4642(22)00191-2</pub-id><pub-id pub-id-type="pmid">35987208</pub-id><pub-id pub-id-type="pmcid">PMC9482947</pub-id></element-citation></ref><ref id="B26-viruses-17-01246"><label>26.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National AIDS and STI Control Programme (NASCOP)</collab></person-group><article-title>Preliminary KENPHIA 2018 Report</article-title><comment>Published Online 2020</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf" ext-link-type="uri">https://phia.icap.columbia.edu/wp-content/uploads/2020/04/KENPHIA-2018_Preliminary-Report_final-web.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-20">(accessed on 20 July 2025)</date-in-citation></element-citation></ref><ref id="B27-viruses-17-01246"><label>27.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National AIDS and STI Control Programme (NASCOP)</collab></person-group><article-title>Kenya HIV Estimates 2015</article-title><comment>Published online October 2016</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nsdcc.go.ke/wp-content/uploads/2021/08/Kenya-HIV-Estimates-2015.pdf" ext-link-type="uri">https://nsdcc.go.ke/wp-content/uploads/2021/08/Kenya-HIV-Estimates-2015.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-20">(accessed on 20 July 2025)</date-in-citation></element-citation></ref><ref id="B28-viruses-17-01246"><label>28.</label><element-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Beck</surname><given-names>I.A.</given-names></name><name name-style="western"><surname>Boyce</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Oldroyd</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>du Toit</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saimen</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramarope</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Hitchcock</surname><given-names>S.</given-names></name><name name-style="western"><surname>du Plessis</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Mbogo</surname><given-names>L.</given-names></name><etal/></person-group><article-title>HIV resistance to dolutegravir varies with co-administered agents</article-title><source>Clin Infect Dis.</source><year>2025</year><comment><italic toggle="yes">in press</italic></comment><pub-id pub-id-type="doi">10.1093/cid/ciaf481</pub-id><pub-id pub-id-type="pmid">40898778</pub-id></element-citation></ref><ref id="B29-viruses-17-01246"><label>29.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Ministry of Health, National AIDS and STI Control Program (NASCOP)</collab></person-group><article-title>Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya, 2018 Edition</article-title><comment>Published Online August 2018</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cquin.icap.columbia.edu/wp-content/uploads/2017/04/ICAP_CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf" ext-link-type="uri">https://cquin.icap.columbia.edu/wp-content/uploads/2017/04/ICAP_CQUIN_Kenya-ARV-Guidelines-2018-Final_20thAug2018.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-21">(accessed on 21 July 2025)</date-in-citation></element-citation></ref><ref id="B30-viruses-17-01246"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>The Lancet HIV</collab></person-group><article-title>End resistance to dolutegravir roll-out</article-title><source>Lancet HIV</source><year>2020</year><volume>7</volume><fpage>e593</fpage><pub-id pub-id-type="doi">10.1016/S2352-3018(20)30231-9</pub-id><pub-id pub-id-type="pmid">32890495</pub-id></element-citation></ref><ref id="B31-viruses-17-01246"><label>31.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Ministry of Health, National AIDS and STI Control Programme (NASCOP)</collab></person-group><article-title>Kenya HIV Prevention and Treatment Guidelines, 2022 Edition</article-title><comment>Published Online August 2022</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.differentiatedservicedelivery.org/wp-content/uploads/Kenya-ARV-Guidelines-2022-Final-1.pdf" ext-link-type="uri">https://www.differentiatedservicedelivery.org/wp-content/uploads/Kenya-ARV-Guidelines-2022-Final-1.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-10">(accessed on 10 July 2025)</date-in-citation></element-citation></ref><ref id="B32-viruses-17-01246"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>R.W.</given-names></name></person-group><article-title>The HIVdb system for HIV-1 genotypic resistance interpretation</article-title><source>Intervirology</source><year>2012</year><volume>55</volume><fpage>98</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1159/000331998</pub-id><pub-id pub-id-type="pmid">22286876</pub-id><pub-id pub-id-type="pmcid">PMC7068798</pub-id></element-citation></ref><ref id="B33-viruses-17-01246"><label>33.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><article-title>List of WHO-Designated Laboratories for HIV Drug Resistance Surveillance, November 2022</article-title><comment>Published Online November 2022</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/list_of_who-designated_hiv_drug_resistance_laboratories_november_2022.pdf?sfvrsn=c2b253ac_8" ext-link-type="uri">https://cdn.who.int/media/docs/default-source/hq-hiv-hepatitis-and-stis-library/list_of_who-designated_hiv_drug_resistance_laboratories_november_2022.pdf?sfvrsn=c2b253ac_8</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-07-20">(accessed on 20 July 2025)</date-in-citation></element-citation></ref><ref id="B34-viruses-17-01246"><label>34.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>National Public Health Institute</collab></person-group><article-title>National HIV Reference Lab. Kenya National Public Health Institute</article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nphi.go.ke/national-hiv-reference-lab" ext-link-type="uri">https://www.nphi.go.ke/national-hiv-reference-lab</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-08-04">(accessed on 4 August 2025)</date-in-citation></element-citation></ref><ref id="B35-viruses-17-01246"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahluwalia</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Inzaule</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baggaley</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Vitoria</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>H.-M.A.</given-names></name><name name-style="western"><surname>Rodolph</surname><given-names>M.</given-names></name><name name-style="western"><surname>Giron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M.R.</given-names></name></person-group><article-title>Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis</article-title><source>AIDS</source><year>2022</year><volume>36</volume><fpage>1897</fpage><lpage>1898</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000003322</pub-id><pub-id pub-id-type="pmid">36172874</pub-id><pub-id pub-id-type="pmcid">PMC9594132</pub-id></element-citation></ref><ref id="B36-viruses-17-01246"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rhee</surname><given-names>S.-Y.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Raizes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parkin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kantor</surname><given-names>R.</given-names></name><name name-style="western"><surname>Van Zyl</surname><given-names>G.U.</given-names></name><name name-style="western"><surname>Mukui</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hosseinipour</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Frenkel</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><fpage>e0145772</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0145772</pub-id><pub-id pub-id-type="pmid">26717411</pub-id><pub-id pub-id-type="pmcid">PMC4696791</pub-id></element-citation></ref><ref id="B37-viruses-17-01246"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wensing</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Calvez</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ceccherini-Silberstein</surname><given-names>F.</given-names></name><name name-style="western"><surname>Charpentier</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gunthard</surname><given-names>H.F.</given-names></name><name name-style="western"><surname>Jacobsen</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Richman</surname><given-names>D.D.</given-names></name></person-group><article-title>2025 update of the drug resistance mutations in HIV-1</article-title><source>Top. Antivir. Med.</source><year>2025</year><volume>33</volume><fpage>457</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">40472382</pub-id></element-citation></ref><ref id="B38-viruses-17-01246"><label>38.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Vizzotto</surname><given-names>A.D.B.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Elkis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cordeiro</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Buchain</surname><given-names>P.C.</given-names></name></person-group><article-title>Psychosocial Characteristics</article-title><source>Encyclopedia of Behavioral Medicine</source><person-group person-group-type="editor"><name name-style="western"><surname>Gellman</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Turner</surname><given-names>J.R.</given-names></name></person-group><publisher-name>Springer</publisher-name><publisher-loc>New York, NY, USA</publisher-loc><year>2013</year><fpage>1578</fpage><lpage>1580</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-1005-9_918</pub-id></element-citation></ref><ref id="B39-viruses-17-01246"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Friedland</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Gottert</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hows</surname><given-names>J.</given-names></name><name name-style="western"><surname>Baral</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Sprague</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nyblade</surname><given-names>L.</given-names></name><name name-style="western"><surname>McClair</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Anam</surname><given-names>F.</given-names></name><name name-style="western"><surname>Geibel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kentutsi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The People Living with HIV Stigma Index 2.0: Generating critical evidence for change worldwide</article-title><source>AIDS</source><year>2020</year><volume>34</volume><issue>(Suppl. S1)</issue><fpage>S5</fpage><lpage>S18</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000002602</pub-id><pub-id pub-id-type="pmid">32881790</pub-id><pub-id pub-id-type="pmcid">PMC11758485</pub-id></element-citation></ref><ref id="B40-viruses-17-01246"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monahan</surname><given-names>P.O.</given-names></name><name name-style="western"><surname>Shacham</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reece</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kroenke</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ong&#8217;oR</surname><given-names>W.O.</given-names></name><name name-style="western"><surname>Omollo</surname><given-names>O.</given-names></name><name name-style="western"><surname>Yebei</surname><given-names>V.N.</given-names></name><name name-style="western"><surname>Ojwang</surname><given-names>C.</given-names></name></person-group><article-title>Validity/reliability of PHQ-9 and PHQ-2 depression scales among adults living with HIV/AIDS in western Kenya</article-title><source>J. Gen. Intern. Med.</source><year>2009</year><volume>24</volume><fpage>189</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1007/s11606-008-0846-z</pub-id><pub-id pub-id-type="pmid">19031037</pub-id><pub-id pub-id-type="pmcid">PMC2629000</pub-id></element-citation></ref><ref id="B41-viruses-17-01246"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marano</surname><given-names>G.</given-names></name><name name-style="western"><surname>del Castillo</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Chieffo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Monti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Janiri</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moccia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sani</surname><given-names>G.</given-names></name></person-group><article-title>Intimate partner violence: A loop of abuse, depression and victimization</article-title><source>World J. Psychiatry</source><year>2021</year><volume>11</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.5498/wjp.v11.i6.215</pub-id><pub-id pub-id-type="pmid">34168968</pub-id><pub-id pub-id-type="pmcid">PMC8209536</pub-id></element-citation></ref><ref id="B42-viruses-17-01246"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Moreno</surname><given-names>C.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>H.A.F.M.</given-names></name><name name-style="western"><surname>Ellsberg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>L.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>C.H.</given-names></name></person-group><article-title>Prevalence of intimate partner violence: Findings from the WHO multi-country study on women&#8217;s health and domestic violence</article-title><source>Lancet</source><year>2006</year><volume>368</volume><fpage>1260</fpage><lpage>1269</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(06)69523-8</pub-id><pub-id pub-id-type="pmid">17027732</pub-id></element-citation></ref><ref id="B43-viruses-17-01246"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casimir</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Tobi</surname><given-names>H.</given-names></name></person-group><article-title>Defining and using the concept of household: A systematic review</article-title><source>Int. J. Consum. Stud.</source><year>2011</year><volume>35</volume><fpage>498</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1111/j.1470-6431.2011.01024.x</pub-id></element-citation></ref><ref id="B44-viruses-17-01246"><label>44.</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name name-style="western"><surname>Coates</surname><given-names>J.</given-names></name><name name-style="western"><surname>Swindale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bilinsky</surname><given-names>P.</given-names></name></person-group><article-title>Household Food Insecurity Access Scale (HFIAS) for Measurement of Household Food Access: Indicator Guide (v. 3)</article-title><comment>Published Online August 2007</comment><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fantaproject.org/sites/default/files/resources/HFIAS_ENG_v3_Aug07.pdf" ext-link-type="uri">https://www.fantaproject.org/sites/default/files/resources/HFIAS_ENG_v3_Aug07.pdf</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-06-20">(accessed on 20 June 2025)</date-in-citation></element-citation></ref><ref id="B45-viruses-17-01246"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heller</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Givens</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Kindig</surname><given-names>D.A.</given-names></name></person-group><article-title>Keeping It Political and Powerful: Defining the Structural Determinants of Health</article-title><source>Milbank Q.</source><year>2024</year><volume>102</volume><fpage>351</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1111/1468-0009.12695</pub-id><pub-id pub-id-type="pmid">38363858</pub-id><pub-id pub-id-type="pmcid">PMC11176401</pub-id></element-citation></ref><ref id="B46-viruses-17-01246"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantor</surname><given-names>R.</given-names></name></person-group><article-title>INSTI era resistance: Emerging concern or marginal issue?</article-title><source>Lancet HIV</source><year>2023</year><volume>10</volume><fpage>e696</fpage><lpage>e698</lpage><pub-id pub-id-type="doi">10.1016/S2352-3018(23)00259-X</pub-id><pub-id pub-id-type="pmid">37832568</pub-id></element-citation></ref><ref id="B47-viruses-17-01246"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haberer</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kiwanuka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nansera</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ragland</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mellins</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bangsberg</surname><given-names>D.R.</given-names></name></person-group><article-title>Multiple Measures Reveal Antiretroviral Adherence Successes and Challenges in HIV-Infected Ugandan Children</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e36737</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0036737</pub-id><pub-id pub-id-type="pmid">22590600</pub-id><pub-id pub-id-type="pmcid">PMC3348916</pub-id></element-citation></ref><ref id="B48-viruses-17-01246"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bearden</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Sportiello</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mweemba</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lungu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Mwanza-Kabaghe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Birbeck</surname><given-names>G.</given-names></name></person-group><article-title>Adherence, Adverse Events and Viral Control among Children and Adolescents with HIV in Zambia Switched to an Integrase Inhibitor Regimen</article-title><source>medRxiv</source><year>2024</year><fpage>medRxiv:2024.09.17.24313837</fpage><pub-id pub-id-type="doi">10.1101/2024.09.17.24313837</pub-id></element-citation></ref><ref id="B49-viruses-17-01246"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gamell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ntamatungiro</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Luwanda</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Battegay</surname><given-names>M.</given-names></name><name name-style="western"><surname>Furrer</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hatz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Felger</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: An emerging public health concern</article-title><source>AIDS</source><year>2017</year><volume>31</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001273</pub-id><pub-id pub-id-type="pmid">27677163</pub-id><pub-id pub-id-type="pmcid">PMC5131685</pub-id></element-citation></ref><ref id="B50-viruses-17-01246"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khamadi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Bahemana</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dear</surname><given-names>N.</given-names></name><name name-style="western"><surname>Mavere</surname><given-names>C.</given-names></name><name name-style="western"><surname>George</surname><given-names>F.</given-names></name><name name-style="western"><surname>Kapene</surname><given-names>R.</given-names></name><name name-style="western"><surname>Papianus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Willoughby</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chambers</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Factors Associated With Viral Suppression and Drug Resistance in Children and Adolescents Living With HIV in Care and Treatment Programs in Southern Tanzania</article-title><source>J. Pediatr. Infect. Dis. Soc.</source><year>2023</year><volume>12</volume><fpage>353</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1093/jpids/piad040</pub-id><pub-id pub-id-type="pmcid">PMC10312299</pub-id><pub-id pub-id-type="pmid">37279560</pub-id></element-citation></ref><ref id="B51-viruses-17-01246"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Onadja</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nandi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Foro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>T.</given-names></name></person-group><article-title>What lies behind gender inequalities in HIV/AIDS in sub-Saharan African countries: Evidence from Kenya, Lesotho and Tanzania</article-title><source>Health Policy Plan.</source><year>2014</year><volume>29</volume><fpage>938</fpage><lpage>949</lpage><pub-id pub-id-type="doi">10.1093/heapol/czt075</pub-id><pub-id pub-id-type="pmid">24345343</pub-id><pub-id pub-id-type="pmcid">PMC4186212</pub-id></element-citation></ref><ref id="B52-viruses-17-01246"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nesamoney</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Mej&#237;a-Guevara</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cislaghi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Weber</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Mbizvo</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Darmstadt</surname><given-names>G.L.</given-names></name></person-group><article-title>Social normative origins of the taboo gap and implications for adolescent risk for HIV infection in Zambia</article-title><source>Soc. Sci. Med.</source><year>2022</year><volume>312</volume><fpage>115391</fpage><pub-id pub-id-type="doi">10.1016/j.socscimed.2022.115391</pub-id><pub-id pub-id-type="pmid">36183540</pub-id><pub-id pub-id-type="pmcid">PMC9582197</pub-id></element-citation></ref><ref id="B53-viruses-17-01246"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levy</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Darmstadt</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Ashby</surname><given-names>C.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halsey</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nagar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>M.E.</given-names></name></person-group><article-title>Characteristics of successful programmes targeting gender inequality and restrictive gender norms for the health and wellbeing of children, adolescents, and young adults: A systematic review</article-title><source>Lancet Glob. Health</source><year>2020</year><volume>8</volume><fpage>e225</fpage><lpage>e236</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30495-4</pub-id><pub-id pub-id-type="pmid">31879212</pub-id><pub-id pub-id-type="pmcid">PMC7025324</pub-id></element-citation></ref><ref id="B54-viruses-17-01246"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Embleton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Logie</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Ngure</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kimbo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ayuku</surname><given-names>D.</given-names></name><name name-style="western"><surname>Turan</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Braitstein</surname><given-names>P.</given-names></name></person-group><article-title>Intersectional Stigma and Implementation of HIV Prevention and Treatment Services for Adolescents Living with and at Risk for HIV: Opportunities for Improvement in the HIV Continuum in Sub-Saharan Africa</article-title><source>AIDS Behav.</source><year>2023</year><volume>27</volume><issue>(Suppl. S1)</issue><fpage>162</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s10461-022-03793-4</pub-id><pub-id pub-id-type="pmid">35907143</pub-id><pub-id pub-id-type="pmcid">PMC10192191</pub-id></element-citation></ref><ref id="B55-viruses-17-01246"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campbell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cornish</surname><given-names>F.</given-names></name></person-group><article-title>Towards a &#8220;fourth generation&#8221; of approaches to HIV/AIDS management: Creating contexts for effective community mobilisation</article-title><source>AIDS Care</source><year>2010</year><volume>22</volume><issue>(Suppl. S2)</issue><fpage>1569</fpage><lpage>1579</lpage><pub-id pub-id-type="doi">10.1080/09540121.2010.525812</pub-id><pub-id pub-id-type="pmid">21161761</pub-id></element-citation></ref><ref id="B56-viruses-17-01246"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Warner</surname><given-names>A.</given-names></name></person-group><article-title>Moving forward on women&#8217;s gender-related HIV vulnerability: The good news, the bad news and what to do about it</article-title><source>Glob. Public Health</source><year>2011</year><volume>6</volume><fpage>S370</fpage><lpage>S382</lpage><pub-id pub-id-type="doi">10.1080/17441692.2011.617381</pub-id><pub-id pub-id-type="pmid">22011135</pub-id></element-citation></ref><ref id="B57-viruses-17-01246"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shannon</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leiter</surname><given-names>K.</given-names></name><name name-style="western"><surname>Phaladze</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hlanze</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Heisler</surname><given-names>M.</given-names></name><name name-style="western"><surname>Iacopino</surname><given-names>V.</given-names></name><name name-style="western"><surname>Weiser</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Kissinger</surname><given-names>P.</given-names></name></person-group><article-title>Gender inequity norms are associated with increased male-perpetrated rape and sexual risks for HIV infection in Botswana and Swaziland</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><fpage>e28739</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0028739</pub-id><pub-id pub-id-type="pmid">22247761</pub-id><pub-id pub-id-type="pmcid">PMC3256140</pub-id></element-citation></ref><ref id="B58-viruses-17-01246"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Subedar</surname><given-names>H.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chaka</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dladla</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hagerman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>S.</given-names></name><name name-style="western"><surname>Matshimane</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mangold</surname><given-names>K.</given-names></name><name name-style="western"><surname>Msimanga</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pooe</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Tackling HIV by empowering adolescent girls and young women: A multisectoral, government led campaign in South Africa</article-title><source>BMJ</source><year>2018</year><volume>363</volume><fpage>k4585</fpage><pub-id pub-id-type="doi">10.1136/bmj.k4585</pub-id><pub-id pub-id-type="pmid">30530572</pub-id><pub-id pub-id-type="pmcid">PMC6284473</pub-id></element-citation></ref><ref id="B59-viruses-17-01246"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Parkhurst</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Ogden</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Aggleton</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mahal</surname><given-names>A.</given-names></name></person-group><article-title>Structural approaches to HIV prevention</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>764</fpage><lpage>775</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60887-9</pub-id><pub-id pub-id-type="pmid">18687460</pub-id></element-citation></ref><ref id="B60-viruses-17-01246"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billioux</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Grabowski</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Ssekasanvu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bazaale</surname><given-names>J.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>E.U.</given-names></name><name name-style="western"><surname>Bugos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ndyanabo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kisakye</surname><given-names>A.</given-names></name><etal/></person-group><article-title>HIV viral suppression and geospatial patterns of HIV antiretroviral therapy treatment facility use in Rakai, Uganda</article-title><source>AIDS</source><year>2018</year><volume>32</volume><fpage>819</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1097/QAD.0000000000001761</pub-id><pub-id pub-id-type="pmid">29369167</pub-id><pub-id pub-id-type="pmcid">PMC5854528</pub-id></element-citation></ref><ref id="B61-viruses-17-01246"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mee</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rice</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kabudula</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Tollman</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>G&#243;mez-Oliv&#233;</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Reniers</surname><given-names>G.</given-names></name></person-group><article-title>The impact of HIV status on the distance traveled to health facilities and adherence to care. A record-linkage study from rural South Africa</article-title><source>J. Glob. Health</source><year>2020</year><volume>10</volume><fpage>020435</fpage><pub-id pub-id-type="doi">10.7189/jogh.10.020435</pub-id><pub-id pub-id-type="pmid">33312502</pub-id><pub-id pub-id-type="pmcid">PMC7719896</pub-id></element-citation></ref><ref id="B62-viruses-17-01246"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akullian</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Mukose</surname><given-names>A.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Babigumira</surname><given-names>J.B.</given-names></name></person-group><article-title>People living with HIV travel farther to access healthcare: A population-based geographic analysis from rural Uganda</article-title><source>J. Int. AIDS Soc.</source><year>2016</year><volume>19</volume><fpage>20171</fpage><pub-id pub-id-type="doi">10.7448/IAS.19.1.20171</pub-id><pub-id pub-id-type="pmid">26869359</pub-id><pub-id pub-id-type="pmcid">PMC4751409</pub-id></element-citation></ref><ref id="B63-viruses-17-01246"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kloos</surname><given-names>H.</given-names></name><name name-style="western"><surname>Assefa</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Adugna</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mulatu</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Mariam</surname><given-names>D.H.</given-names></name></person-group><article-title>Utilization of antiretroviral treatment in Ethiopia between February and December 2006: Spatial, temporal, and demographic patterns</article-title><source>Int. J. Health Geogr.</source><year>2007</year><volume>6</volume><fpage>45</fpage><pub-id pub-id-type="doi">10.1186/1476-072X-6-45</pub-id><pub-id pub-id-type="pmid">17894877</pub-id><pub-id pub-id-type="pmcid">PMC2045665</pub-id></element-citation></ref><ref id="B64-viruses-17-01246"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adeneye</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Adewole</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Musa</surname><given-names>A.Z.</given-names></name><name name-style="western"><surname>Onwujekwe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Odunukwe</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Araoyinbo</surname><given-names>I.D.</given-names></name><name name-style="western"><surname>Gbajabiamila</surname><given-names>T.A.</given-names></name><name name-style="western"><surname>Ezeobi</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Idigbe</surname><given-names>E.O.</given-names></name></person-group><article-title>Limitations to Access and Use of Antiretroviral Therapy (ART) Among HIV Positive Persons in Lagos, Nigeria</article-title><source>World Health Popul.</source><year>2006</year><volume>8</volume><fpage>46</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.12927/whp.2006.18134</pub-id><pub-id pub-id-type="pmid">18277101</pub-id></element-citation></ref><ref id="B65-viruses-17-01246"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lankowski</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Siedner</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bangsberg</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>A.C.</given-names></name></person-group><article-title>Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: A systematic review</article-title><source>AIDS Behav.</source><year>2014</year><volume>18</volume><fpage>1199</fpage><lpage>1223</lpage><pub-id pub-id-type="doi">10.1007/s10461-014-0729-8</pub-id><pub-id pub-id-type="pmid">24563115</pub-id><pub-id pub-id-type="pmcid">PMC4047127</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-17-01246-f001" orientation="portrait"><label>Figure 1</label><caption><p>Flow diagram of participants included for analysis from Opt4Kids parent and extension studies (<italic toggle="yes">n</italic> = 704).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-01246-g001.jpg"/></fig><fig position="float" id="viruses-17-01246-f002" orientation="portrait"><label>Figure 2</label><caption><p>Distribution of HIV drug resistance mutations defined in Stanford HIVdb taken from sequence with greatest drug resistance penalty score <italic toggle="yes">N</italic> = number of children with mutations to the respective drug class(es). (<bold>a</bold>) Distribution of all drug resistance mutations by drug class and select codons; (<bold>b</bold>) distribution of NRTI mutations; (<bold>c</bold>) distribution of NNRTI mutations; (<bold>d</bold>) distribution of PI mutations; and (<bold>e</bold>) distribution of INSTI mutations. (NRTIs&#8212;nucleoside reverse transcriptase inhibitors; NNRTIs&#8212;non-nucleoside reverse transcriptase inhibitors; INSTI&#8212;integrase strand transfer inhibitors; PIs&#8212;protease inhibitors). Note: Mutations categorized as &#8220;Other&#8221; had a prevalence below the 1.3% cutoff threshold established by our team and were therefore excluded from the figure.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-01246-g002.jpg"/></fig><fig position="float" id="viruses-17-01246-f003" orientation="portrait"><label>Figure 3</label><caption><p>Prevalence (and 95% confidence intervals) of Stanford HIVdb drug resistance penalty scores &#8805; 30 to available antiretroviral agents derived from mutations detected in participants Note: Abbreviations: NRTIs&#8212;nucleoside reverse transcriptase inhibitors; NNRTIs&#8212;non-nucleoside reverse transcriptase inhibitors; INSTI&#8212;integrase strand transfer inhibitors; PIs&#8212;protease inhibitors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-01246-g003.jpg"/></fig><fig position="float" id="viruses-17-01246-f004" orientation="portrait"><label>Figure 4</label><caption><p>Forest plot of factors associated with a drug resistance penalty score &#8805; 30 to any antiretroviral agent assessed by Stanford HIVdb detected in children enrolled in Opt4Kids parent and/or extension studies (<italic toggle="yes">n</italic> = 704) from the multivariate model output. Note: Abbreviations: ART&#8212;antiretroviral therapy; DRM&#8212;drug resistance mutation; NNRTI&#8212;non-nucleoside reverse transcriptase inhibitor; INSTI&#8212;integrase strand transfer inhibitor; PI&#8212;protease inhibitor.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-17-01246-g004.jpg"/></fig><table-wrap position="float" id="viruses-17-01246-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-17-01246-t001_Table 1</object-id><label>Table 1</label><caption><p>Characteristics of children enrolled in Opt4Kids by detection of HIV drug resistance (<italic toggle="yes">n</italic> = 704).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Total<break/><italic toggle="yes">n</italic> = 704</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Children Without DR testing or DR-PS &lt; 30<break/><italic toggle="yes">n</italic> = 611</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Children with DR-PS &#8805; 30<break/><italic toggle="yes">n</italic> = 93</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (%)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">N</italic> (%)</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Child Clinical Characteristics</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, median (IQR)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (7, 12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (7, 12)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (5, 12)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age category (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#8211;5</td><td align="center" valign="middle" rowspan="1" colspan="1">79 (11.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (9.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (25.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#8211;10</td><td align="center" valign="middle" rowspan="1" colspan="1">301 (42.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">269 (44.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (34.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11&#8211;15</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">324 (46.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">287 (47.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (39.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male</td><td align="center" valign="middle" rowspan="1" colspan="1">360 (51.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">313 (51.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (48.04)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">344 (48.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">298 (48.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53 (51.96)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">History of VF within two years prior to enrolling in Opt4Kids</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">144 (20.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">87 (14.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">57 (61.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">504 (71.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">476 (77.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (30.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (8.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (7.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Base drug in ART regimen at time of DR test analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NNRTI-containing</td><td align="center" valign="middle" rowspan="1" colspan="1">363 (51.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">343 (56.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (21.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PI-containing</td><td align="center" valign="middle" rowspan="1" colspan="1">285 (40.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">240 (39.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">45 (48.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">INSTI-containing</td><td align="center" valign="middle" rowspan="1" colspan="1">55 (7.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (4.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">28 (30.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only NRTI-containing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Co-administered NRTIs at time of DR test analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC</td><td align="center" valign="middle" rowspan="1" colspan="1">479 (68.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">425 (69.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (58.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC</td><td align="center" valign="middle" rowspan="1" colspan="1">135 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">115 (18.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">20 (21.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF + 3TC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">90 (12.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71 (11.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (20.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Full ART regimen at the time of DR test analysis <sup>1</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<underline>NNRTI-containing</underline>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">203 (28.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">194 (31.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC + NVP</td><td align="center" valign="middle" rowspan="1" colspan="1">47 (6.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">42 (6.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">5 (5.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC + NVP</td><td align="center" valign="middle" rowspan="1" colspan="1">41 (5.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (6.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (1.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (1.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF + 3TC + EFV</td><td align="center" valign="middle" rowspan="1" colspan="1">60 (8.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (9.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (4.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<underline>PI-containing</underline>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC + LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">198 (28.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">172 (28.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (28.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC + LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">72 (10.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (9.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (15.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (0.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF + 3TC + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF + 3TC + LPV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<underline>INSTI-containing</underline>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (0.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC + DTG</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (4.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (2.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">14 (15.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC + DTG</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (0.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF + 3TC + DTG</td><td align="center" valign="middle" rowspan="1" colspan="1">21 (3.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (1.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (12.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<underline>Other</underline>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">TDF + 3TC + DTG + ATV/r</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AZT + 3TC + ABC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Frequency of resistance to multiple drugs (DR-PS &gt; 30) within an ART drug class <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRTI&#8212;1 drug</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">3 (3.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NRTI&#8212;&gt;2 drugs</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (74.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NNRTI&#8212;1 drug</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NNRTI&#8212;&gt;2 drugs</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">82 (88.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PI&#8212;1 drug</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PI&#8212;&gt;2 drugs</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (6.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">INSTI&#8212;1 drug</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">-</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">INSTI&#8212;&gt;2 drugs</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (3.2)</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Caregiver Clinical Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age of caregiver</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;24 years</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (5.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (5.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24&#8211;35 years</td><td align="center" valign="middle" rowspan="1" colspan="1">325 (46.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">272 (44.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (57.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&gt;35 years</td><td align="center" valign="middle" rowspan="1" colspan="1">336 (47.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">305 (49.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (33.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver viral suppression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">431 (61.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">379 (62.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (55.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">39 (5.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">30 (4.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">9 (9.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Not applicable</td><td align="center" valign="middle" rowspan="1" colspan="1">135 (19.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (19.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">19 (20.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">99 (14.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">86 (14.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (14.0)</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Child Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">School level</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nursery</td><td align="center" valign="middle" rowspan="1" colspan="1">124 (17.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">107 (17.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">17 (18.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Primary</td><td align="center" valign="middle" rowspan="1" colspan="1">512 (72.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">454 (74.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">58 (62.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Secondary</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 </td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64 (9.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">46 (7.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (19.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">School type</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Day school</td><td align="center" valign="middle" rowspan="1" colspan="1">631 (89.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">557 (91.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">74 (79.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Boarding</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">4 (0.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">0 </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Mix of day and boarding</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62 (8.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (7.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (19.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ART adherence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Good</td><td align="center" valign="middle" rowspan="1" colspan="1">558 (79.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">499 (81.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (63.4)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">146 (20.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">112 (18.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (36.6)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adolescence awareness of status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">408 (58.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">352 (57.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (60.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">296 (42.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">259 (42.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (39.8)</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Caregiver Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver marital status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" rowspan="1" colspan="1">442 (62.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">380 (62.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">62 (66.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Unmarried</td><td align="center" valign="middle" rowspan="1" colspan="1">261 (97.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">230 (37.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (33.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Educational attainment of caregiver</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No Education</td><td align="center" valign="middle" rowspan="1" colspan="1">29 (4.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">27 (4.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">2 (2.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Primary</td><td align="center" valign="middle" rowspan="1" colspan="1">398 (56.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">344 (56.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (58.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary &amp; above</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">277 (39.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">240 (39.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37 (39.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver depression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">252 (35.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">205 (34.75)</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (43.0) </td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">451 (64.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">398 (65.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">53 (57.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver stigma</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">105 (14.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">93 (15.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">12 (12.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">505 (71.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">436 (71.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">69 (74.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94 (13.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82 (13.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (12.9)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">HIV literacy</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">331 (47.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">287 (47.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">49 (52.7)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">373 (53.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">324 (53.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (47.3)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Medicine administration confidence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">665 (94.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">582 (95.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">83 (89.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">39 (5.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">29 (4.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (10.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver intimate partner violence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">163 (23.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">140 (22.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (24.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">540 (76.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">470 (76.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (75.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Household Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Food insecurity</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">16 (2.3)</td><td align="center" valign="middle" rowspan="1" colspan="1">15 (2.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">687 (97.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">595 (97.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">92 (98.9)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.1)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.2)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other children in the home</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">630 (89.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">544 (89.0)</td><td align="center" valign="middle" rowspan="1" colspan="1">86 (92.5)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">71 (10.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">64 (10.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (7.5)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.4)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other CLHIV in the home</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes </td><td align="center" valign="middle" rowspan="1" colspan="1">107 (15.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">96 (15.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">11 (11.8)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">593 (84.2)</td><td align="center" valign="middle" rowspan="1" colspan="1">512 (83.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">81 (87.1)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Missing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (0.6)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (0.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1.1)</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Structural Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Travel time to facility</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;30 min </td><td align="center" valign="middle" rowspan="1" colspan="1">231 (32.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">188 (30.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">43 (46.2)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30 min to 1 h</td><td align="center" valign="middle" rowspan="1" colspan="1">309 (43.9)</td><td align="center" valign="middle" rowspan="1" colspan="1">278 (45.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">31 (33.3)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;1 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">164 (23.3)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">145 (23.7)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (20.4)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clinic location</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Urban</td><td align="center" valign="middle" rowspan="1" colspan="1">421 (59.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">367 (60.1)</td><td align="center" valign="middle" rowspan="1" colspan="1">54 (58.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Semi-urban</td><td align="center" valign="middle" rowspan="1" colspan="1">158 (22.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">132 (21.6)</td><td align="center" valign="middle" rowspan="1" colspan="1">26 (28.0)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rural</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">125 (17.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">106 (17.97)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (14.0)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clinic population volume</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Heavy</td><td align="center" valign="middle" rowspan="1" colspan="1">203 (28.8)</td><td align="center" valign="middle" rowspan="1" colspan="1">180 (29.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (24.7)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Medium</td><td align="center" valign="middle" rowspan="1" colspan="1">439 (62.4)</td><td align="center" valign="middle" rowspan="1" colspan="1">383 (62.7)</td><td align="center" valign="middle" rowspan="1" colspan="1">56 (60.2)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Light</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">62 (8.8)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">48 (7.9)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (15.1)</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ABC&#8212;Abacavir; ART&#8212;antiretroviral therapy; ATV/r&#8212;Atazanavir/Ritonavr; AZT&#8212;Zidovudine; CLHIV&#8212;children living with human immunodeficiency virus; DR&#8212;drug resistance; DR-PS&#8212;drug resistance penalty score; DTG&#8212;Dolutegravir; EFV&#8212;Efavirenz; LPV/r&#8212;Lopinavir/Ritonavir; INSTI&#8212;integrase strand transfer inhibitor; NRTI&#8212;nucleoside reverse transcriptase inhibitor; NNRTI&#8212;non-nucleoside reverse transcriptase inhibitor; NVP&#8212;Nevirapine; PI&#8212;protease inhibitor; TDF&#8212;Tenofovir; VF&#8212;virological failure (defined as viral load &#8805; 1000 copies/mL); 3TC&#8212;Lamivudine. <sup>1</sup> For participants without a DR test, a proxy test date was assigned based on the median time from enrollment to DR test among those who were tested. <sup>2</sup> Percentages may sum to more than 100 percent because participants can have drug resistance (DR) to multiple ART drug classes simultaneously.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-17-01246-t002" orientation="portrait"><object-id pub-id-type="pii">viruses-17-01246-t002_Table 2</object-id><label>Table 2</label><caption><p>Factors associated with a drug resistance penalty score (DR-PS) &lt; 30 (i.e., ART-suppressed or DR-PS &lt; 30) versus a DR-PS &#8805; 30 to any antiretroviral agent assessed by Stanford HIVdb that was detected in children enrolled in Opt4Kids studies (<italic toggle="yes">n</italic> = 704).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Unadjusted RR <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Adjusted RR <sup>1</sup></th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Child Clinical Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age category (years)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">1&#8211;5</td><td align="center" valign="middle" rowspan="1" colspan="1">2.66 (1.69, 4.18)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.84 (1.07, 3.14)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6&#8211;10</td><td align="center" valign="middle" rowspan="1" colspan="1">0.93 (0.60, 1.45)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.753</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 (0.51, 1.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.211</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11&#8211;15 (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Sex</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Male (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Female</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.02 (0.70, 1.5)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.901</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">History of VF within two years prior to enrolling in Opt4Kids</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">7.13 (4.72, 10.76)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">4.18 (2.77, 6.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Base drug in ART regimen at time of DR test analysis</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">NNRTI-containing (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">PI-containing</td><td align="center" valign="middle" rowspan="1" colspan="1">2.87 (1.73, 4.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">6.05 (3.43, 10.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">INSTI-containing</td><td align="center" valign="middle" rowspan="1" colspan="1">9.24 (5.61, 15.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" rowspan="1" colspan="1">1.83 (1.08, 3.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.026</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Only NRTI-containing <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Co-administered NRTIs at time of DR test analysis <sup>3</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ABC + 3TC (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">AZT + 3TC</td><td align="center" valign="middle" rowspan="1" colspan="1">1.31 (0.82, 2.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.260</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TDF + 3TC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.87 (1.17, 3.0)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.009</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Caregiver Clinical Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Age of caregiver</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;24 years</td><td align="center" valign="middle" rowspan="1" colspan="1">2.44 (1.25, 4.75)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.009</td><td align="center" valign="middle" rowspan="1" colspan="1">1.10 (0.64, 1.87)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.738</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24&#8211;35 years</td><td align="center" valign="middle" rowspan="1" colspan="1">1.77 (1.17, 2.68)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.007</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 (0.86, 1.91)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.226</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;35 years (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver viral suppression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.91 (1.02, 3.58)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.043</td><td align="center" valign="middle" rowspan="1" colspan="1">1.37 (0.74, 2.54)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.321</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Not applicable</td><td align="center" valign="middle" rowspan="1" colspan="1">1.17 (0.72, 1.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.537</td><td align="center" valign="middle" rowspan="1" colspan="1">1.21 (0.80, 1.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.356</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.09 (0.62, 1.92)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.769</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.42 (0.83, 2.45)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.202</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Child Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">School level</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Nursery (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Primary</td><td align="center" valign="middle" rowspan="1" colspan="1">0.83 (0.50, 1.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.458</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">School type</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.832</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Day school</td><td align="center" valign="middle" rowspan="1" colspan="1">0.82 (0.13, 5.1)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Boarding <sup>2</sup></td><td align="center" valign="middle" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mix of day and boarding (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">ART adherence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Good (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poor</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2 (1.51, 3.22)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.91 (1.32, 2.76)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Adolescence awareness of status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No</td><td align="center" valign="middle" rowspan="1" colspan="1">1.1 (0.75, 1.62)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.636</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Caregiver Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver marital status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.419</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Married</td><td align="center" valign="middle" rowspan="1" colspan="1">1.18 (0.79, 1.77)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Unmarried (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown <sup>2</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">-</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver educational attainment</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No Education</td><td align="center" valign="middle" rowspan="1" colspan="1">0.52 (0.13, 2.03)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.345</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Primary</td><td align="center" valign="middle" rowspan="1" colspan="1">1.02 (0.69, 1.5)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.937</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Secondary &amp; above (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver depression</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.122</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">1.02 (0.70, 1.49)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.916</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (0.92, 1.98)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver stigma</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.543</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">0.84 (0.47, 1.49)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver HIV literacy</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.951</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">0.99 (0.68, 1.44)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver medicine administration confidence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.05 (1.16, 3.64)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.014</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.89 (1.11, 3.22)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.019</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Caregiver intimate partner violence</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.09 (0.7, 1.69)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.704</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Household Psychosocial Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Household food insecurity</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.14 (0.32, 14.43)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.434</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other children in the household</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">0.382</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes</td><td align="center" valign="middle" rowspan="1" colspan="1">1.38 (0.67, 2.87)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Other CLHIV in the household</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Yes (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">No</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.33 (0.73, 2.41)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.349</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Structural Characteristics</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Time to facility</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">&lt;30 min (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30 min to 1 h</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 (0.35, 0.83)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.004</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 (0.47, 1.12)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.144</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&gt;1 h</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.62 (0.38, 1.03)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.064</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.71 (0.44, 1.14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.156</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clinic location</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Rural</td><td align="center" valign="middle" rowspan="1" colspan="1">0.81 (0.46, 1.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.472</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Semi-urban</td><td align="center" valign="middle" rowspan="1" colspan="1">1.28 (0.83, 1.97)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.257</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urban (Ref)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Clinic volume</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Light (Ref)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.0</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Medium</td><td align="center" valign="middle" rowspan="1" colspan="1">0.56 (0.34, 0.95)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.024</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 (0.33, 0.92)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.023</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heavy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 (0.28, 0.91)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.032</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.76 (0.41, 1.39)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.371</td></tr></tbody></table><table-wrap-foot><fn><p>Abbreviations: ABC&#8212;Abacavir; ART&#8212;antiretroviral therapy; AZT&#8212;Zidovudine; CLHIV&#8212;children living with human immunodeficiency virus; DR-PS&#8212;drug resistance penalty score; NRTI&#8212;nucleoside reverse transcriptase inhibitor; NNRTI&#8212;non-nucleoside reverse transcriptase inhibitor; INSTI&#8212;integrase strand transfer inhibitor; IPV&#8212;intimate partner violence; PI&#8212;protease inhibitor; RR&#8212;relative risk; TDF&#8212;Tenofovir; VF&#8212;virological failure (defined as viral load &#8805; 1000 copies/mL); 3TC&#8212;Lamivudine. <sup>1</sup> Relative risks were estimated using a Poisson regression model with robust standard errors; adjusted models included age, history of virological failure within two years prior to study, base drug in ART regimen at time of DR test analysis, age of caregiver, caregiver viral suppression, adherence, caregiver depression, medicine administration confidence, time to facility, and clinic volume. The observations with missing data were excluded; the extent of missingness is summarized in <xref rid="viruses-17-01246-t001" ref-type="table">Table 1</xref>. <sup>2</sup> The relative risk cannot be calculated when the frequency of one of the categories is 0 which leads to quasi-complete separation and prevents proper estimation. <sup>3</sup> Not included in adjusted models due to collinearity with base ART regimen at index DRM result. Bold text indicates estimates with <italic toggle="yes">p</italic>-values &lt; 0.05.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>